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As the list of drugs becoming perceived as neurotoxic is growing, its chronic use has been 
raising increased concern. The anti-human immunodeficiency virus (HIV)-infection drug 
efavirenz (EFV) clearly illustrates these circumstances, being a drug chronically used by both 
adults and children, for which neurotoxic effects have been consistently recognized. In order to 
develop preventive/management strategies, the understanding of the mechanisms underlying 
EFV-induced neurotoxicity is crucial towards the mechanistic-oriented discovery of suitable 
biomarkers for their evaluation. Theses biomarkers will be ethically obtained and ideally will 
be easily accessed from peripheral biofluids, allowing the evaluation of patient´s risk, the 




A significant number of individuals on the recommended dose of EFV have central nervous 
system (CNS) adverse reactions, which represent the main drawback of EFV. These adverse 
reactions also constitute a major factor for EFV discontinuation, limiting adherence to 
combined antiretroviral therapy and available therapeutic options. The prevention and 
management of these neuro-adverse reactions are hampered by their broad-spectrum nature 
(from sleep disturbances to mood-changes or memory impairment) that might involve distinct 
underlying mechanisms. Clinical trials have consistently described a high inter-patient 
variability for type, time to onset, duration and severity of the CNS complaints. Most of 
EFV-induced CNS-adverse reactions are reversible and tend to occur during the first weeks of 
treatment. However, EFV discontinuation continues to occur late in the course of treatment, 
due to the persistence of CNS toxicity which may negatively impact the health and quality of 
life of patients on a long-term basis. While short-term effects are usually transient, or if not 
they are normally a factor for drug switch, the long-term effects are much more difficult to 
predict and to manage.  
 
 
Patient´s individual metabolic capability is considered a factor on these neuro-adverse 
reactions, taking into consideration the high inter-patient variability in EFV concentrations and 
pharmacogenomic data. In particular, strong non-clinical evidence supports that EFV major 
Phase I metabolite, 8-hydroxy-efavirenz (8-OH-EFV) is a more potent neurotoxin than EFV 
itself. Nonetheless, the relevance of these findings to a clinically useful neuro-safety evaluation 
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has yet to be demonstrated. Mostly, due to difficulties on the quantification of 8-OH-EFV levels 




Due to these premises, the overall goals of the present translational research project were to 
study the mechanism underlying EFV-induced long-term CNS adverse reactions and to identify 
peripheral markers for the risk assessment of EFV-induced neurotoxicity and for the evaluation 
of strategies for prevention and management of these toxic events. 
 
 
Towards these goals, firstly we have performed a clinical study aimed at investigating the 
CYP2B6 activity and 8-OH-EFV generation as an upstream event of mood changes in patients 
on long-term EFV exposure. A case-control study was performed, with two age-matched 
groups of HIV-infected male patients: a group without adverse CNS complaints and a group 
presenting mood changes. A high-performance liquid chromatography method was developed 
and validated to quantify the plasmatic concentrations of EFV, 8-OH-EFV and 8-hydroxy-
efavirenz-glucuronide. Secondly, aiming at disclosing the role of EFV biotransformation and 
Cyp2b auto-induction in the mechanism underlying EFV short- and long-term toxicity, we used 
an animal model to study tissue- and time-dependency of biotransformation, auto-induction and 
oxidative stress-related thiolomic signature. This evaluation was performed in brain (prefrontal 
cortex and hippocampus) and liver from Wistar male rats on short (10 days) and long-term (36 
days) EFV exposure. Third, in the same animal model we have evaluated the neurological, 
histopathological and molecular phenotype representative of long-term exposure to EFV. With 
this methodological approach the main findings arising from this project were:  
 
1. The metabolism into 8-OH-EFV is associated with EFV-related mood changes upon 
long-term EFV exposure, which suggests that the concentration of this metabolite is a 
suitable parameter to perform therapeutic drug monitoring aimed at 
preventing/controlling these manifestations; 
 
2. The time-course of Cyp2b mediated-EFV biotransformation justifies different 
mechanisms for its short- and long-term neurotoxicity. Upon long-term EFV exposure, 
a decrease in the neuronal function occurs in hippocampus, which is associated with 
learning and memory impairment. This is coincident with an accumulation of 8-OH-






3. Cyp2b auto-induction effects and oxidative stress-related thiolomic signature upon 
EFV exposure is tissue- and time-dependent and helps to explain why this antiretroviral 
is mainly biotransformed at the liver but it is barely hepatotoxic. 
 
 
If translated to clinical practice, these evidences will have important implications in 
EFV-prescription as well as short- and long-term neurotoxicity prevention and management.  
 
 
Keywords: 8-hydroxy-efavirenz, neurotoxicity, CYP2B6 drug biotransformation, thiolomic 










Como o número de fármacos com potencial neurotóxico tem vindo a aumentar, existe uma 
preocupação crescente com a sua utilização, principalmente de forma crónica.  
O fármaco antirretroviral efavirenz (EFV) ilustra bem estas circunstâncias. Trata-se de um 
fármaco destinado a uso crónico, pela população adulta e pediátrica, e cujos efeitos 
neurotóxicos têm sido amplamente descritos. Com o objetivo de desenvolver estratégias 
dirigidas à prevenção e minimização destes efeitos, torna-se crucial a clarificação dos 
mecanismos subjacentes à sua neurotoxicidade. De facto, é imperativo encontrar 
biomarcadores apropriados para avaliar a neurotoxicidade associada à administração do EFV. 
Idealmente, a obtenção destes biomarcadores deve ser realizada de forma eticamente aceitável 
e através da recolha de fluidos biológicos periféricos, assegurando a avaliação de estratégias 
implementadas com vista a minimização da toxicidade relacionada com o fármaco.   
	
	
O número de indivíduos medicados com a dose recomendada de EFV que desenvolvem reações 
adversas no Sistema Nervoso Central (SNC) é bastante significativo, sendo estas a principal 
desvantagem inerente ao uso deste fármaco. Estes eventos constituem também um fator 
limitante da adesão à terapêutica antirretroviral combinada por parte dos doentes e das opções 
terapêuticas disponíveis. O controlo e a prevenção do aparecimento destas reações de 
neurotoxicidade são dificultadas pela panóplia de efeitos que podem estar associados à 
administração deste fármaco (e.g. distúrbios do sono, alterações de humor, perda de memória) 
e, pela forte plausibilidade dos mecanismos que lhes são subjacentes serem distintos. Os 
estudos clínicos têm descrito de forma consistente a existência de uma elevada variabilidade 
inter-individual para o tipo, início, duração e gravidade das reações adversas. Estas são, na sua 
maioria, reversíveis e tendem a ocorrer durante as primeiras semanas de tratamento. Ainda 
assim, a descontinuação do fármaco, motivada pelo aparecimento destas manifestações, 
continua a observar-se em tratamentos de longa duração, condicionando um impacto negativo 
na saúde e qualidade de vida dos doentes. Se, por um lado, os efeitos a curto prazo são 
geralmente transitórios ou motivadores da interrupção da terapêutica com este fármaco, por 
outro, os efeitos a longo prazo são muito menos previsíveis e de difícil controlo. 
	
	
Tendo em consideração a elevada variabilidade inter-individual das concentrações de EFV e 
aos dados farmacogenéticos que têm vindo a ser descritos, a capacidade metabólica inerente a 
cada doente constitui um fator preponderante para o desenvolvimento das reações adversas. Em 
concreto, dados obtidos de estudos não-clínicos indicam que o principal metabolito de fase I 
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do EFV, o 8-hidroxi-efavirenz (8-OH-EFV), é uma neurotoxina mais potente que o próprio 
EFV. No entanto, até ao momento, não foi elucidada a relevância destes resultados numa 
avaliação clínica da sua segurança neurológica. Este facto deve-se principalmente à dificuldade 
em quantificar os metabolitos reativos do 8-OH-EFV e/ou os níveis de adutos formados por 
estes no cérebro, dada a inacessibilidade a este tecido alvo. 
 
 
Tendo em consideração as premissas descritas, os objetivos gerais delineados para o presente 
projeto translacional foram o estudo dos mecanismos subjacentes às reações adversas induzidas 
pelo uso prolongado do EFV e a identificação de possíveis marcadores periféricos que 
permitam a avaliação do risco de desenvolvimento de neurotoxicidade, bem como de 
estratégias destinadas à sua prevenção e controlo.  
 
 
Para a concretização destes objetivos foi primeiramente realizado um estudo clínico, com o 
intuito de investigar a atividade do CYP2B6 e a formação do 8-OH-EFV no desenvolvimento 
de alterações de humor, em indivíduos medicados com EFV de modo crónico. Em concreto, 
foi implementado um estudo caso-controlo, que envolveu dois grupos de doentes do sexo 
masculino, infetados pelo VIH e com idades comparáveis: um grupo sem queixas a nível do 
SNC e um outro com alterações de humor. Foi também desenvolvido e validado um método de 
cromatografia líquida de alta eficiência para quantificar as concentrações plasmáticas de EFV, 
de 8-OH-EFV e do seu metabolito glucurono-conjugado. Posteriormente, com o intuito de 
elucidar o papel da biotransformação do EFV e da sua auto-indução no mecanismo subjacente 
à sua toxicidade, foi usado um modelo animal. Avaliaram-se a biotransformação, a 
auto-indução e o perfil “tiolómico” relacionado com o stress oxidativo em diferentes tecidos e 
em animais expostos ao EFV por diferentes períodos. Em concreto, esta avaliação centrou-se 
no cérebro (córtex pré-frontal e hipocampo) e no fígado de ratos machos Wistar expostos ao 
EFV por um período curto (10 dias) e por um período longo (36 dias). Por último, foi realizado 
um estudo comportamental e uma avaliação histopatológica e molecular das duas áreas do 
cérebro de ratos expostos a EFV por 36 dias. Através desta abordagem metodológica foi 
possível obter as seguintes conclusões principais: 
 
1.   A formação de 8-OH-EFV está associada a alterações de humor induzidas pela exposição 
ao EFV por um longo período de tempo. Este facto sugere que a concentração deste 
metabolito é um parâmetro adequado para a prática da monitorização da terapêutica, tendo 





2.  A biotransformação do EFV mediada pelo Cyp2b, ao longo do tempo, justifica a 
existência de mecanismos diferentes responsáveis pela sua neurotoxicidade a curto e longo 
prazo. A exposição continuada ao EFV por um longo período de tempo está associada a um 
decréscimo da função neuronal no hipocampo e diminuição da capacidade de aprendizagem 
e memória. Estes factos são coincidentes com uma acumulação de 8-OH-EFV no plasma e 
expressão de Cyp2b aumentada no fígado e diminuída no hipocampo; 
 
3.   A auto-indução do Cyp2b e o perfil tiolómico relacionado com o stress oxidativo são 
dependentes do tecido e do tempo de exposição ao EFV. Esta observação pode ajudar a 
explicar o porquê do EFV, apesar de ser maioritariamente metabolizado no fígado, não 
evidenciar um perfil hepatotóxico clinicamente relevante; 
 
 
A translação destas observações para a prática clínica poderá ter implicações importantes na 
prescrição do EFV, bem como na prevenção e controlo da neurotoxicidade associada a este 
fármaco a curto e longo prazo. 
 
	
Palavras-chave: 8-hidroxi-efavirenz, neurotoxicidade, CYP2B6, biotransformação de 
fármacos, perfil tiolómico, monitorização terapêutica de fármacos, perda de memória, 






























1. Human immunodeficiency virus (HIV)-infection in brief 
 
At 35 years ago, the scientific community has known the human immunodeficiency virus (HIV) 
infection, unaware of the social and economic impact that it would have worldwide as well as 
it severity and transversely to sex, age and transmission route. The history of HIV-infection 
started in the early 80´s with a description of pneumonia and Kaposi’s sarcoma in five 
homosexual patients with compromised immune response (Gottlieb et al., 1981). Once 
classified as gay-related immune deficiency, the occurrence of this cluster of signs and 
symptomatology rapidly spread independently of sexual orientation, sex, age or race and was 
thereafter defined as acquired immune deficiency syndrome (AIDS) (Herek and Glunt, 1988).  
Two years were gone from those observations, when HIV was identified as the cause of AIDS 
(Barré-Sinoussi et al., 1983; Gallo et al., 1983) and several studies have presented the first 
cases of HIV-infected individuals among those that received blood transfusions, as 
hemophiliacs (CDC, 1982c); inmates, mostly drug addicts (Wormser et al., 1983); healthcare 
workers  (CDC, 1982b); woman (Harris et al., 1983) and children (CDC, 1982a). At the 
beginning of the epidemic, without available therapy, the survival rate after diagnosis was 
measured in weeks or months and healthcare delivery was only based in HIV diagnosis and on 
control and treatment of AIDS-related opportunistic infections or malignancies. During the next 
years this epidemic was considered an acute disease with serious implications in the patient’s 
life expectancy, which declined considerably. Since then, HIV was responsible for about 78 
million infections and more than 35 million deaths (UNAIDS, 2016). 
 
In short, the course of non-controlled HIV-infection starts with a clinical latent period, 
asymptomatic, with active viral replication associated with a progressive destruction of the 
cluster of differentiation 4 (CD4+) cells (AETC, 2014). This stage can last an average of 8-11 
years, depending on several factors including the person´s health status and life style.  In this 
latency period, there are enough immune cells to afford a response against the infection. But, a 
significant number of T cells are eventually destroyed and the rate of its production cannot 
follow the rate of its destruction, triggering the patient to the symptomatic stage. After this, an 





2. The combined antiretroviral therapy and HIV-infection conversion into 
a chronic disease   
 
The urgency of achieving a treatment to stop this pandemic, triggered a wave of research 
combining laboratory and clinical sciences that allowed the discovery of HIV replication cycle 
(Fig. 1). This was the starting point for the massive pharmacological research and ultimately 
opened a new era for drug development. The Food and Drug Administration (FDA) approved 
the first antiretroviral drug (ARV), zidovudine, in 1987 (Brook, 1987). Only two years were 
passed between the in vitro tests of zidovudine anti-HIV efficacy and its approval (Mitsuya et 
al., 1985), showing the urgent need of a weapon to fight this pandemic. However, it was soon 
realized that its use in monotherapy would fail due to viral drug resistance (Larder and Kemp, 
1989). In the 90's, to surpass drug resistance, the association of three or more drugs acting on 
different steps of HIV cycle, the combined antiretroviral therapy (cART), was preconized and 
radically changed the natural history of HIV-infection (Palella et al., 2006). Nowadays, there 
are more than 20 available ARVs and it is estimated that an individual diagnosed with HIV-
infection at 20 years of age that starts cART will live 50 or more years after diagnosis 
(Dieffenbach and Fauci, 2011). The cART is an example of how the research and investment 
in drug development can change the natural course of a disease, with an unprecedented 
availability of several drugs in a short period of time, allowing the HIV-infection to be currently 
perceived as a chronic disease (Fauci, 2003; Mehellou and De Clercq, 2010). 
 
The cART comprises different alternatives of ARVs combinations, which clinicians try to be 
the most adapted to each patient. ARVs do not cure HIV-infection, but reduce significantly the 
amount of virus (viral load) in the patients’ body as well as the deleterious AIDS-related 
consequences. Nowadays, the European and American guidelines for HIV therapy recommend 
cART use at any CD4+ cell count or HIV stage (AIDSinfo, 2016; EACS, 2016). 
 
ARVs are distributed in six classes according to their mechanism of action in the different steps 
of HIV life cycle (Fig. 1). Efavirenz (EFV) (Fig. 2) belongs to the non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) that inhibit reverse transcriptase in a non-competitive manner 
(De Clercq, 2004). The first-line cART is composed by three drugs, two of which are 
nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus one of the following options: a 
protease inhibitor (PI) boosted with ritonavir; a integrase strand transfer inhibitors (INSTI); or 







Figure 1. Schematic overview of the main steps of the human immunodeficiency virus (HIV)-life 
cycle and the targets for antiretroviral drugs.  The CCR5 antagonist (1), block the binding the viral 
glycoprotein 120 to the chemokine receptor 5 of the host cell; FI (2), fusion inhibitors bind to the viral 
glycoprotein 41 preventing the fusion of HIV with the host cell membrane; NNRTIs (4), non-nucleoside 
reverse transcriptase inhibitors, inhibit reverse transcriptase in a non-competitive manner; NRTIs (4), 
nucleoside/nucleotide reverse transcriptase inhibitors are analogues of the naturally occurring 
deoxynucleotides that first must be phosphorylated to their pharmacologically triphosphate derivate, to 
later competitively inhibit the virus reverse transcriptase; INSTIs (6), integrase strand transfer inhibitors 
target the integrase activity, which is the viral enzyme responsible for the integration of the viral DNA 
into the host cell genome; PI (13), protease inhibitors, block HIV protease, which is the responsible for 
cleavage precursor polyproteins to structural proteins (eg. p24) and functional proteins (eg. reverse 
transcriptase). In: Engelman and Cherepanov (2016). 
 
Occasionally, the cART regimens need to be altered - for example in case of virological failure, 
adverse reactions, pregnancy, co-infections or drug interactions - and alternative cART need to 
be adopted. The levels of HIV RNA (viral load) are the preferred method for monitoring the 
response to cART. There should be at least 1 log reduction in the viral load, preferably to less 
than 10,000 copies/ml, within 2-4 weeks after the beginning of cART (AIDSinfo, 2016; EACS, 
2016). If a lower reduction in viral load is observed or if it stays above 100,000 copies/mL the 
treatment should then be adjusted, by either adding or switching drugs. After six months, viral 
load should be maintained lower than 20 copies/mL (bellow quantification level). If it returns 
to 0.3-0.5 log of pre-treatment levels or there are two consecutive failures in attaining 
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undetectable value, the efficacy of cART is compromised and it should be changed. Viral load 
measurement should be repeated every 4-6 months in patients clinically stables (AIDSinfo, 
2016; EACS, 2016).  CD4+ count is also used for monitoring cART efficacy (importantly before 
starting therapy). When CD4+ drops to baseline or below 50% of increase from pre-treatment 
(approximately 30 cells.mm-3) then the cART should also be changed. CD4+ counts should be 
obtained every 3-6 months during periods of clinical stability and more frequently when 
symptomatic disease occurs (AIDSinfo, 2016; EACS, 2016). 
 
 
3. HIV-infection panorama in combined antiretroviral therapy era: a 
matter of antiretroviral toxicity 
 
At the end of 2015, the cART was available for 17 million people worldwide (UNAIDS, 2015). 
Chronic treatment with cART is presently unavoidable. Since the cART implementation, the 
causes of death of HIV-infected patients considerably changed from AIDS-related to 
non-AIDS-related diseases (Palella et al., 2006). This might be explained by the fact that 
patients live longer and several complications related with the normal aging process emerge at 
an earlier age, including cancer, cardiovascular, neurocognitive, liver and renal diseases (ATC, 
2008; Deeks and Phillips, 2009). Furthermore, treated patients have persistent 
infection/inflammation, residual viremia, compromised immune system that together with life 
style risk factors (e.g. smoke and alcohol), co-infections (e.g. hepatitis and tuberculosis), 
drug-drug interactions, and importantly, the chronic exposure to antiretroviral toxicity, put 
HIV-infected population at higher risk of premature aging (Deeks and Phillips, 2009). Thus, 
nowadays there is an increasing concern about the toxic effects induced by ARVs, in particular 
those arising from long-term use. The adverse reactions of ARVs have a negative impact on 
clinical outcomes, ultimately affecting the life quality and expectancy of the patients. The 
management of toxicity outcomes also requires additional hospital visits and admissions, 
increasing the economic burden on already strained medical care systems (Núñez et al., 2006).  
 
 
4. The antiretroviral Efavirenz  
 
4.1 Pros and cons 
 
EFV (Fig. 2) was approved by FDA in 1998 (Vazquez, 1998) and is currently one of the most 




This antiretroviral is prescribed in combination with abacavir/lamivudine (Kivexa®) with 
tenofovir/emtricitabine (Truvada®) or in one-pill fixed-dose combination with 
tenofovir/emtricitabine (Atripla®). The availability of one pill combination significantly 
improved cART adherence, a major predictor of cART success, due to the simplicity and the 
lower quantity of pills that patients have to take daily (Maggiolo, 2009; Airoldi et al., 2010). 
Additionally, EFV is an option during treatment with rifampicin for tuberculosis (AIDSinfo, 
2016). These facts together with the availability of a generic EFV and its consequent lower 
price justify the high prescription of this drug.  
Despite its benefits, EFV is associated to toxic effects that limit its use. For instance, based on 
animal studies and retrospective case-reports, FDA classified EFV as a pregnancy category D 
medication. In pregnancy this drug might be associated with neural tube and/or central nervous 
system (CNS) abnormalities (Ford et al., 2011). Thus, special care should be given to women 
on EFV in reproductive age. These women may conceive while on EFV-based cART and 
continue EFV therapy during the high risk first trimester, before their pregnancy is diagnosed. 
Nevertheless, women diagnosed in the second or third trimester of pregnancy needing cART 
can receive EFV without a malformation concern (Bristol-Myers Squibb, 2015). 
While liver and skin toxicity are less common (Phillips et al., 2002; Rivero et al., 2007), a 
significant number of individuals on the recommended EFV dose display CNS adverse 
reactions (Fumaz et al., 2005; Kenedi and Goforth, 2011; Apostolova et al., 2015b). These 
effects represent the main drawback of EFV and are a major factor for its discontinuation 
(Leutscher et al., 2013), limiting adherence and available cART options. EFV-CNS adverse 
reactions are of broad spectrum and consist mainly of sleep disturbances and other neurological 
symptoms (Kenedi and Goforth, 2011; Apostolova et al., 2015b). Notably, up to 35% of 
patients on EFV-containing cART manifest mood-changes symptomatology (Fumaz et al., 
2005; Tashima et al., 2008) and 40-50% present cognitive disorders, whereas 23-29% are 
related to memory (Lochet et al., 2003; Ma et al., 2016). In the few data available about EFV 
tolerability in children, the same CNS adverse reactions observed in adults were reported 
(Teglas et al., 2001; Tukei et al., 2012). 
Most of EFV-neuro adverse reactions occur at a snapshot in time, during the first weeks of 
treatment and soon they fade away (short-term toxicity) (Fumaz et al., 2005). However, they 
can persist for long-term in a significant proportion of patients, which may impact negatively 
patient’s quality of life and lead to later EFV discontinuation (Leutscher et al., 2013). In 
consequence of these adverse reactions, in the current year actualization, both European and 
American antiretroviral guidelines no longer recommend this NNRTI as first-line therapy as it 




4.2 EFV pharmacology 
 
The recommended dose of EFV is the oral daily intake of 600 mg for adults and adolescents 
(AIDSinfo, 2016). For children up to 3 years old and with more than 10 kg, EFV dose should 
be adjusted to their weight (AIDSinfo, 2016). Steady state maximal concentration (Cmax) and 
area under the curve (AUC) are 4.07 mg/L (achieved in 3 to 5 h, Tmax) and 58.1 mg/L.h, 
respectively (Adkins and Noble, 1998). The half-life (t1/2) of EFV is 19 h after long-term 
prescription of EFV containing cART in HIV-population (Csajka et al., 2003), much shorter 
from what was described in non-HIV volunteers (40 – 55 h) (Adkins and Noble, 1998).  
 
EFV is highly bounded to plasma proteins (> 99%), mainly albumin. This NNRTI is widely 
distributed, and it has been reported to accumulate in cells, reaching intracellular concentrations 
above its 90% inhibitory concentration (Almond et al., 2005).   EFV is able to cross the blood-
brain barrier and reach the cerebrospinal fluid (CSF) with concentrations between 0.5 to 1.2% 
of its corresponding plasma concentrations. These concentrations represent the therapeutic 
concentration in brain, once these values are enough to inhibit HIV replication in CSF (Tashima 
et al., 1999; Best et al., 2011; Ene, 2011). The fact that EFV has a good penetration in brain is 
an advantage; since brain is an HIV reservoir, i.e., a compartment where HIV can persist for 
long periods of time in a quiescent state contributing to virus persistence.  
EFV is predominantly biotransformed at the liver by cytochrome P450 (CYP) 2B6, with 
CYP3A4, CYP3A5, CYP1A2 and CYP2A6 being minor contributors (Ward et al., 2003; 
Bélanger et al., 2009; di Iulio et al., 2009; Ogburn et al., 2010). CYP2B6 is mostly responsible 
for the hydroxylation of EFV into 8-hydroxy-efavirenz (8-OH-EFV) (Fig. 2) (Ward et al., 
2003). Subsequent metabolic pathways of this metabolite include phase II conjugations, 
primarily glucuronidation (major) by multiple UDP-glucuronosyltransferases (UGTs) (Bae et 
al., 2011) and sulfonation (minor) (Aouri et al., 2016). Further oxidation into 8,14-dihydroxy-
efavirenz (8,14-diOH-EFV, Fig. 2) is also possible by CYP2B6 isoform; however, this 
metabolite has been barely detected in man and no correlation with EFV-induced toxic events 
was identified to date (Belanger et al., 2009; Bae et al., 2011; Cho et al., 2011; Avery et al., 
2013a). The formation of 8,14-di-OH-EFV is somehow not consensual. In vitro studies have 
shown that this metabolite was not produced when the 8-OH-EFV was incubated in human 
liver microsomes (Ogburn et al., 2010). Accordingly, 8,14-di-OH-EFV is barely detected 
plasma. While the phase II 8,14-di-OH-EFV was found in urine, suggesting that 8-OH-EFV 
may first undergo a phase II conjugation step prior to the second hydroxylation at position 14 




al., 2010), can also yield 7-hydroxy-efavirenz (7-OH-EFV, Fig. 2), which is a minor non-toxic 
metabolite (Tovar-y-Romo et al., 2012). Phase I metabolites are present at low levels in plasma 
(Cho et al., 2011; Avery et al., 2013, Aouri et al, 2016) whereas the phase II metabolites 
(8-OH-EFV-glucuronide (8-OH-EFV-Glc), 7-OH-EFV-Glc and 7-OH-EFV-sulfate) are found 
at comparable or even higher levels than EFV itself (Aouri et al., 2016). In fact, 8-OH-EFV 
and 8-OH-EFV-Glc are the major phase I and phase II metabolites, respectively, and both have 
been quantified in plasma, urine and CSF (Aouri et al., 2016). The predominant mode of EFV 
elimination is through glucuronide metabolites in urine, with less than 1% of EFV eliminated 
in the unchanged form (U.S. Food and Drug Administration, 2015). 
	
EFV is an inducer of its own metabolism through CYP2B6 (Ngaimisi et al., 2010). This auto 
induction is dose-, duration of treatment- and genetically-dependent, resulting in lower EFV 
plasma concentrations (Ngaimisi et al., 2010; Habtewold et al., 2011). The induction period 
persists for long-term and is characterized by a growing 8-OH-EFV formation (Ngaimisi et al., 
2010). This induction period is also highly variable among patients in extension and magnitude 
(Ngaimisi et al., 2010). 
 
Being a substrate (Ward et al., 2003), inhibitor (Xu and Desta, 2013) or inducer (Robertson et 
al., 2008) of CYP450 and other enzymes and drug transporters, EFV has high potential for drug 
interactions. Some of these interactions and their management are well defined. An example is 
the co-administration of EFV and the tuberculostatic rifampicin, where a dose adjustment of 
EFV to 800 mg per day is recommended (Bristol-Myers Squibb, 2015).  
 
While the drug transporters influencing the pharmacokinetics (PK) of EFV and its metabolites 
still to be properly identified, it is known that EFV inhibits several members of multidrug 







Figure 2. Efavirenz main biotransformation routes.  
7-OH-EFV, 7-hydroxy-efavirenz; 7-OH-EFV-Glc, 7-hydroxy-efavirenz-glucuronide; 7-OH-EFV-sulf, 
7-hydroxy-efavirenz-sulfate; 8-OH-EFV, 8-hydroxy-efavirenz; 8-OH-EFV-Glc, 
8-hydroxy-efavirenz-glucuronide; 8-OH-EFV-sulf, 8-hydroxy-efavirenz-sulfate; 8,14-diOH-EFV, 
8,14-dihydroxy-efavirenz; EFV, efavirenz; SULT, sulfotransferases; UGT, 
UDP-glucuronosyltransferases. 
 
This NNRTI has a narrow therapeutic window (Marzolini et al., 2001; Gutiérrez et al., 2005; 
Pereira et al., 2008) and exhibits considerable inter-individual variability in clinical response 
(Stahle et al., 2004), which might be related to adherence issues, PK variability and drug 
interactions. In the beginning of the twenty-century, almost in parallel with the implementation 
of cART, the utility of therapeutic drug monitoring (TDM) was proposed as a mean to optimize 
response to ARV therapy (Aarnoutse et al., 2003). TDM is a strategy based on repeated 
quantifications of drugs (drugs with a narrow therapeutic range) in patients’ blood, with the 
aim of optimize drug response and give to the clinician the rational for an individualized 
treatment (Back et al., 2002; Ivanovic et al., 2008). The application of TDM to EFV was based 
on the following criteria: efficacy/toxicity relationship, high inter-patient variability, low 
intra-individual variability, high potential to drug interactions and a narrow therapeutic window 
(Ghiculescu, 2008). Marzolini and colleagues (2001) have defined the therapeutic window of 
EFV between 1-4 mg/L. In concentrations below 1 mg/L patients are exposed to 
sub-therapeutic EFV concentrations and are at higher risk of developing HIV resistance, while 
concentrations above 4 mg/L are related to CNS adverse reactions toxicity (Marzolini et al., 
2001). This study has led to a definition of a minimal toxic concentration of 4 mg/L. However, 




EFV-induced neurotoxicity. While several studies support this relationship (Marzolini et al., 
2001; Gutiérrez et al., 2005; Rotger et al., 2005) others did not establish an increased risk of 




5. Mechanisms of EFV-neurotoxicity – what is known? 
 
In the last years, several in vitro and in vivo studies have addressed plausible mechanism and 
key players on EFV neurotoxicity. Hereinafter, the major discoveries related to this topic are 
summarized. They are majorly based on in vitro and rodent approaches and related to EFV 
itself. Only recently, the role of EFV biotransformation into 8-OH-EFV has been focus of 
research.  
To date, the existing in vivo studies on EFV neurotoxicity were performed in different rodent 
strains and only three of them performed behavior evaluation. The first, in 2005, by O´Mahony 
and co-authors have showed that Wistar rats orally exposed to EFV (10 mg/kg) during 34 days 
displayed spatial memory deficits (using Morris Water Maze, MWM) and higher susceptibility 
to stress (evaluated in the open-field test, OF) (O'Mahony et al., 2005). In another study, using 
CF-1 mice, EFV exposure (10 mg/kg during 36 days by oral intake) was associated to an 
anxiogenic-like effect (evaluated by elevated plus maze, EPM), without affecting the 
spontaneous locomotion (OF test). A substantial impairment of aversive memory, assessed by 
the inhibitory avoidance test, was also reported by these authors (Romao et al., 2011). The most 
recent study described that EFV (range 10–30 mg/kg administrated intraperitoneally) induced 
a dose-dependent decrease in the open-field locomotor activity of male ND4 Swiss Webster 
mice and activated a significant head-twitch response in wild-type mice but not in 5-HT2A-KO 
mice (Gatch et al., 2013).   
There are different and probably non-exclusive mechanisms that have been related to these 
observations, such as increase of pro-inflammatory cytokines and serotonin modulation. The 
first was described in Wistar rats orally exposed to EFV (10 mg/kg) during 34 days.  The 
increased pro-inflammatory cytokines, interleukin 1β and tumor necrosis factor-α were 
partially reduced by administration of paroxetine, a selective serotonin reuptake inhibitor 
(O'Mahony et al., 2005). Also, in Sprague-Dawley rats exposed to a concentration of EFV three 
times higher than the therapeutic (30 mg/kg, intraperitoneally), was observed that EFV has a 
similar response as lysergic acid diethylamine (LSD) in drug discriminative procedure, that was 
completely blocked by a selective antagonist of serotonin 2A (5-HT2A) receptor (Gatch et al., 
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2013). Additionally, EFV induced head-twitch response in wild-type mice but not in 
5-HT2A-knockout mice (Gatch et al., 2013). Consubstantiated by radioligand binding assays, 
these authors suggested that EFV has an LSD-like effect in the manner that it can be a partial 
agonist of the 5-HT2A receptor (Gatch et al., 2013). The anomalous activity of 5-HT2A receptor 
have been associated with several psychiatric conditions, including memory and learning 
impairment, mood changes, schizophrenia, and drug addiction (Zhang and Stackman, 2015). 
 
EFV-induced neurotoxicity has also been associated to impairment in mitochondrial function 
and neural bioenergetics. In male CF-1 mice exposed to EFV (10 mg/kg) during 36 days, 
creatine kinase (CK) was diminished in cerebellum, hippocampus, striatum and cortex (Streck 
et al., 2008).  CK is important for energy homeostasis (Wallimann et al., 1992) and a decrease 
in CK activity is associated with neuronal loss following brain ischemia (Tomimoto et al., 
1993), neurodegenerative diseases (Aksenov et al., 2000). Regarding mitochondrial 
impairment EFV affects cortex, striatum and hippocampus, at the level of complex IV activity 
(Streck et al., 2008). In neural stem cells (NSC), EFV reduces cell proliferation, intracellular 
adenosine triphosphate (ATP), mitochondrial membrane potential as well as it increases lactate 
dehydrogenase (LDH) release, p38 MAPK (protein kinases that participate in the response to 
cell stress) activation and Bax expression (pro-apoptotic gene) (Jin et al., 2016). The authors 
replicated the reduction in proliferating NSCs in the subventricular zone of C57BL/6 mice (Jin 
et al., 2016). Other in vitro studies using SH-SY5Y (neurons) and U-251MG (glial cells) cell 
cultures, described a decrease in mitochondrial respiratory function, in a concentration-
dependent manner upon acute EFV exposure (10 µM and 25 µM) (Funes et al., 2015). EFV 
induced a drop in ATP production, which coincided with an increase in autophagy, 
mitochondrial fragmentation and depolarization (Funes et al., 2015). Cell viability/proliferation 
was only reduced in SH-SY5Y. The authors also reproduce these results in primary cultures of 
rat neurons and astrocytes, confirming mitochondrial dysfunction and a higher impairment in 
neurons than astrocytes, which were only slightly affected at a higher concentration of EFV 
(Funes et al., 2014). On opposite, no alterations in mitochondrial respiration were observed 
when rat primary astrocytes culture were exposed to 10 µM of EFV (Brandmann et al., 2013). 
EFV only compromised cell viability at 10-times higher concentration (100 µM) (Brandmann 
et al., 2013). Increasing evidence have been showing the role of mitochondrial dysfunction in 
CNS diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), dementia, 
multiple sclerosis, ataxia, encephalomyopathies, and depression (Maes et al., 1990; Witte et 





 EFV also promotes inducible nitric oxide synthase (iNOS) expression in cultured glial cells 
and generates nitric oxide (NO) (Apostolova et al., 2015a), which might affect mitochondrial 
function and enhance reactive oxygen species (ROS) generation in a concentration-dependent 
manner and in both neurons and glia (Funes et al., 2014). Neuroinflammation and oxidative 
stress are also common features in neurodegenerative diseases. In both AD and PD, oxidative 
stress activates inflammatory signaling pathways through several mechanisms, including 
exacerbating the production of ROS, mitochondrial dysfunction, activating microglia and 
astrocytes to release pro-inflammatory mediators (Whitton, 2007; Schapira, 2010; von 
Bernhardi and Eugenin, 2012).   
EFV increases soluble amyloid beta (Aβ) and β-secretase-1 (BACE-1) expression, that is a key 
enzyme with an important role in Aß formation (Cole and Vassar, 2007). The role of Aß plaques 
formation in AD development is well known (Golde et al., 2000; Sambamurti et al., 2002) as 
these peptides have recognized neurotoxic, oxidative and inflammatory potential (Bradt et al., 
1998; Murakami et al., 2005). By using a murine N2a cells transfected with the human 
“Swedish” mutant form of amyloid precursor protein (SweAPP N2a cells) and Tg2576 mice 
exposed to EFV (15 mg/kg in chow for a period of 10 days) it was shown that this drug is 
capable of promote BACE-1 activity and impair microglial clearance mechanisms, ultimately 
increasing Aß plaques production and leading to the disease profile of Alzheimer (Brown et 
al., 2014).  
More recently, in vitro studies have link neurotoxicity with EFV main metabolite, 8-OH-EFV. 
Using incubated rat hippocampal neuronal cultures with EFV or 8-OH-EFV or 7-OH-EFV it 
was shown that 8-OH-EFV was one order of magnitude more potent in inducing neurotoxicity 
than the others. Also, the minimal neurotoxic 8-OH-EFV concentration was three times lower 
than what is found in the CSF of HIV-infected patients (Tovar-y-Romo et al., 2012). The 
exposure to 8-OH-EFV, in dose-dependent manner (0.01 µM – 10 µM), caused significant 
dendritic spines damage and induced rapid calcium influx in neurons, mediated by L-type 
voltage-operated calcium channels. Neurons appeared to undergo a dramatic loss of membrane 
integrity and release of the calcium probe. Other study showed that 8-OH-EFV stimulates the 
glycolytic flux in rat primary astrocytes culture in a time- and concentration-dependent manner, 
with maximal effects at 10 µM, and enhanced both lactate release and glucose consumption 
(Brandmann et al., 2013). However, on contrary to what was expected no effects were observed 
regarding mitochondrial respiration at10 µM (Brandmann et al., 2013). Another mechanism to 
8-OH-EFV neurotoxicity was proposed by Harjivan and coauthors (2014), that reported the 




6. An overlook on cytochrome P450 2B6 and efavirenz biotransformation 
 
CYPs isoenzymes are heme-containing mixed function oxidases, which are involved in the 
metabolism of several endogenous and exogenous substrates. This superfamily of isoenzymes 
is localized in the endoplasmic reticulum of cells. Currently, there are 17 mammalian CYP gene 
families described that translates into approximately 60 distinct CYP forms (Nelson, 1999),  
displaying species-, sex-, tissue- and age-specific expression patterns, which will influence 
differently drug metabolism, activation, and detoxification. CYP450 enzymes are well 
conserved throughout species and are derived from ~1.36 billion years old ancestral gene (Lin, 
1995). Members of the CYP2B subfamily have been identified among many mammalian 
species including man, monkeys, dogs, rabbits, and rodents (Martignoni et al., 2006). The 
family member CYP2B6 was firstly described in 1989 and it is located on the long-arm of 
chromosome 19 (Yamano et al., 1989). While primarily expressed at the liver, representing 2% 
to 10% of the total hepatic CYP450 content (Wang and Tompkins, 2008), CYP2B6 has also 
been detected in several extrahepatic tissues including brain, kidney, intestine, endometrium, 
peripheral blood lymphocytes and skin (Gervot et al., 1999; Janmohamed et al., 2001; Ding 
and Kaminsky, 2003).  
 
Studies using human liver microsomes have revealed that the formation rate of 8-OH-EFV 
displays considerable variability between samples (Ward et al., 2003), anticipating that EFV 
systemic exposure is likely to rely on inter-individual variability in CYP2B6 activity and with 
drug interactions involving this isoform. This has subsequently been corroborated by several 
pharmacogenetics studies focusing CY2B6 polymorphisms in HIV-infected patients on EFV 
(Nolan et al., 2006). Importantly, EFV hydroxylation into 8-OH-EFV was elected as 
phenotyping tool for the evaluation of CYP2B6-mediated metabolism for in vitro a clinical 
studies by Food and Drug Administration (U. S. Food and Drug Administration, 2016). 
 
Several factors contribute to CYP2B6 activity and might impact EFV biotransformation, such 
as genetics, sex, age, smoking and drug interactions (Zanger and Klein, 2013). Lamba and 
coauthors (2003), by using liver donors (from 80 ethnically mixed samples), showed higher 
amounts of CYP2B6 mRNA (3.9-fold), protein (1.7-fold) and enzyme activity (1.6-fold) among 
females compared to male subjects (Lamba et al., 2003). In another study including 235 
Caucasian individuals, female liver samples had 1.6-fold higher CYP2B6 expression levels 
than man, but this difference did not translate into higher protein or activity levels (Hofmann 
et al., 2008). Contrariwise, higher plasma concentrations were found in female on 




factors as race (these results were observed in non-Caucasians), age or body fat into EFV 
concentrations  (Burger et al., 2006; Nyakutira et al., 2008; Mukonzo et al., 2009).  In fact, 
CYP2B6 phamacogenetics may have a higher contribution to EFV biotransformation than sex 
differences (Burger et al., 2006).  
 
 
6.1. Efavirenz pharmacogenetics 
	
The impact of CYP2B6 genetic variability on EFV response has been one of the most studied 
examples on pharmacogenetic utility in therapeutic response optimization. Most of the 
available data relate genetic variants with EFV concentrations. However, its relation with each 
type of CNS adverse reaction, with the treatment time-point that they occur (shortly after 
beginning or at long-term) and with PK of 8-OH-EFV still very poorly documented. 
 
The variant CYP2B6 516G>T (*6) has been associated to a reduction in enzyme activity and 
elevated EFV plasma concentrations (Arab-Alameddine et al., 2009; Mukonzo et al., 2009; 
Yimer et al., 2012). The studied populations are from different ethnic groups, among which 
CYP2B6*6 occurs at frequencies of 15% to over 60% (Zanger and Klein, 2013). As CYP2B6*6 
is most frequent in the African American and African populations, this has been raising concern 
about EFV dose adjustments in these populations (Zanger and Klein, 2013). CYP2B6*6 
(516G>T) was the genetic variant with the strongest association with EFV neurotoxicity 
(without discriminating the CNS adverse reaction). Also, it was associated to higher plasma 
concentrations at short-term treatment (Gounden et al., 2010) and after one year on EFV 
(Sanchez Martin et al., 2013). In other cohort, CYP2B6*6 was only associated with CNS 
adverse reactions at the first week of treatment but not at week 24 (Haas et al., 2004), when the 
auto-induction of biotransformation period is already near equilibrium (Ngaimisi et al., 2010).  
CYP2B6*6 was associated with a lower magnitude of the auto-induction of EFV 
biotransformation and to a lower 8-OH-EFV formation (Ngaimisi et al., 2010).  
 
Other functionally alleles of CYP2B6 have been studied, for example *18, which is also 
responsible for a reduced expression and activity of the enzyme and its associated with higher 
EFV concentrations (Zanger and Klein, 2013). On the contrary, CYP2B6*22 is responsible for 
a gain of function (higher expression and activity) (Rotger et al., 2007), but until now no 




In a limited number of studies, CYP3A4 and CYP2A6 allelic diversity were also shown to 
influence EFV PK variability, especially in CYP2B6 poor metabolizers (Arab-Alameddine et 
al., 2009). The CYP2A6 polymorphisms are rare among Caucasians and more frequent in 
African populations. The variants CYP2A6*10, *17 and *9 are responsible for a decrease in 
protein activity and increased plasma concentrations of EFV (Nakajima et al., 2006; Kwara et 
al., 2009b).  
 
Most of the pharmacogenetic studies have so far been focused on genetic variations of CYP450 
enzymes, but genetic variations in nuclear receptors, drug transporters or conjugation enzymes 
can also contribute to the observed variability in EFV disposition. Genetic variants in 
constitutive androstane receptor (CAR) (540C>T) contribute to early treatment discontinuation 
of EFV-based regimens (Wyen et al., 2011) and to lower EFV plasma concentrations (Cortes 
et al., 2013). In fact, the induction of CYP2B6 by EFV is promoted by the upregulation of this 
receptor (Meyer Zu Schwabedissen et al., 2012). The UGT2B7 enzyme genetic variants might 
also contribute to variations in EFV plasma concentrations, particularly UGT2B7*1 (low 
enzyme activity), which is responsible for an increase in EFV plasma concentration (Kwara et 
al., 2009a). The 4036A>G and 4036G>G genotypes of ABCB1 were significantly associated 
with lower EFV plasma concentrations, while the ABCB1 1236C>T and 1236T>T genotypes 
were associated with higher EFV concentrations (Swart et al., 2012a).  
 
	
6.2. CYP2B6 substrates, inhibitors and inducers 
 
The number of drugs recognized to be metabolized by CYP2B6 has been continuously 
increasing. This isoenzyme is responsible for the biotransformation of several therapeutic drugs 
that include antiepileptic (e.g. phenytoin (H. Wang et al., 2004)); anticancer (e.g. prodrug of 
cyclophosphamide (Roy et al., 1999)). Bupropion has been considered the probe substrate for 
CYP2B6 activity (Faucette et al., 2000; Hesse et al., 2001). CYP2B6 also metabolizes drugs 
of abuse as nicotine (Yamazaki et al., 1999) and 
3,4-methylenedioxy-methamphetamine (MDMA/ecstasy) (Kreth et al., 2000)); pesticides (e.g. 
chlorpyrifos), pollutants (e.g. benzene) and neurotoxic contaminants (e.g. 
1-methyl--4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)) (D. Lewis, 1996). Anandamide, 
testosterone and serotonin (Rosenbrock et al., 1999; Fradette et al., 2004; Sridar et al., 2011) 
are endogenous substrates of this enzyme.  
 
Among CYP2B6 inhibitors, triethylenethiophosphoramide (thioTEPA) is a strong inhibitor 




2009).  The antiretroviral tenofovir, which might be combined with EFV in cART (AIDSinfo, 
2016) and the antifungal voriconazole are also weak inhibitors (weak) of CYP2B6 (U.S Food 
and Drug Administration, 2016). 
 
Besides EFV, several drugs can induce CYP2B6, being phenobarbital the most recognized 
(Gervot et al., 1999). Others examples include rifampicin (Faucette et al., 2004), phenytoin 
(Wang et al., 2004) and carbamazepine (Oscarson et al., 2006). The ARVs nevirapine, which 
is never co-administrated with EFV (AIDSinfo, 2016) and ritonavir (only administrated in baby 
doses to HIV-infected patients) are also CYP2B6 inducers (Faucette et al., 2007). 
CYP2B6 expression is regulated by both CAR (Sueyoshi et al., 1999) and pregnane X (PXR) 
(Goodwin et al., 2001) receptor. When activated by inducers, these nuclear receptors are 
transported from cytoplasm to the nucleus, bind to DNA and increase CYP2B6 transcription 
(Meyer zu Schwabedissen et al., 2012). The target genes of CAR and PXR broadly overlap and 
both receptors interact with the same response elements in target gene promoters (Smirlis et 
al., 2001). It is also known that together with EFV, nevirapine, carbamazepine, phenytoin 
preferentially and directly interacts with CAR. CAR-mediated EFV auto-induction is 
compartment-specific, occurring at liver and peripheral blood monocular cells (PBMC) but not 
at intestine (Meyer zu Schwabedissen et al., 2012).  
 
 
6.3. Brain CYP2B6   
	
CYP2B6 in the human brain are expressed in a cell- and region-specific manner and possibly 
have different putative roles within the brain (Miksys et al., 2003; Dutheil et al., 2009). 
CYP2B6-expressing brain cells include neurons and astrocytes (Miksys et al., 2003). Together 
with the blood brain barrier (BBB), they create microenvironments in which CYP2B6 play a 
significant role in the local metabolism of substrates (Miksys and Tyndale, 2002) and may 
induce different responses to drugs and their metabolites. For example, most of CYP2B6 
inducers have been studied at the hepatic microsomes (Faucette et al., 2004), while scarce 
information exists about induction in the brain. In human brain CYP2B6 is inducible by 








6.4. Rat CYP2B  
 
Whereas tissue availability makes difficult to study CYP2B6 regulation in man, several 
similarities make the rat a suitable animal model in drug metabolism studies. CYP2B family is 
similar between humans (CYP2B6) and rodents (Cyp2b1 and Cyp2b2), with high homology 
and sharing substrates (Miksys et al., 2000). Similarly, to human brain, Cyp2b1/2 is also present 
in rat brain in a tissue- and cell- dependent manner (Miksys et al., 2000). Its expression is 
mainly regulated by CAR in man (Sueyoshi et al., 1999) and rat Cyp2b has also been described 
to be regulated by the orthologous CAR (Muangmoonchai et al., 2001). The prototypal 
CYP2B6 inducer phenobarbital has been proved as a Cyp2b inducer in rat (Ganem et al., 1999) 
as well as there is Cyp2b induction in brain by nicotine (Miksys et al., 2000), phenobarbital 
(Schilter et al., 2000)  and phenytoin (Rosenbrock et al., 1999). 
 
 
7. Bioactivation of 8-hydroxy-efavirenz – a plausible mechanism for EFV 
neurotoxicity 
	
In vitro studies have recently supported the plausibility of 8-OH-EFV to be bioactivated. When 
exposed to oxidative conditions (by the oxidative agent Frémy’s salt, which is frequently used 
to obtain quinones from phenolic compounds), the 8-OH-EFV was considerably more prone to 
oxidative degradation than 7-OH-EFV, yielding a quinone-imine derivative (Fig. 3) (Wanke et 
al., 2012; Harjivan et al., 2014). Despite the possibility of a catechol intermediate to be formed 
upon 7-OH-EFV oxidation, no quinoid derivative was obtained, under similar oxidative 
conditions. In contrast, a stable metabolite was obtained. These contrasting behaviors under 
oxidative conditions may explain the distinct toxicities of the two phenolic EFV metabolites 
observed in primary rat neuron cultures (Tovar-y-Romo et al., 2012). In fact, quinoid species 
(quinone and quinone-imines) are reactive electrophiles (as Michael acceptors) and can easily 
react with nucleophiles from macromolecules (e.g., proteins and DNA) and generate covalent 
adducts (Bolton et al., 2000; Monks and Jones, 2002). Additionally, due to their pro-oxidant 
activity and redox cycling, these quinoid intermediates are involved in the formation of reactive 
oxygen species. Therefore, the role of quinoid derivatives to electrophilic/oxidative stress, is 
frequently involved in the onset of toxic events. Many electrophilic quinoid species can disrupt 
brain function (Lopachin and Decaprio, 2005). One example is the oxidation of dopamine or 
L-dihydroxyphenylalanine-(L-DOPA) to a quinone metabolite, that is neurotoxic via formation 
of covalent adducts with proteins (Asanuma et al., 2003).Notably, EFV has been associated 




of DNA-adducts formation in CNS compartments (de Oliveira et al., 2014). This observation 
was true for mice exposed to EFV (orally treated with 10 mg/kg EFV) during 36 days (chronic 
administration), but not to those exposed only to a single-dose (acute administration).  
 
 
Figure 3. Distinct behaviors of EFV Phase I metabolites, 7-OH-EFV and 8-OH-EFV, under 
oxidative conditions in vitro. Contrasting with 7-OH-EFV, the main EFV metabolite, 8-OH-EFV, 
affords reactive quinoide metabolite under oxidative conditions. The capacity of these reactive 
metabolites to form covalent adducts with proteins and of promoting oxidative/electrophilic stress may 
explain the role of 8-OH-EFV bioactivation in the onset of EFV-induced neurotoxic events. 7-OH-EFV, 
7-hydroxy-efavirenz; 8-OH-EFV, 8-hydroxy-efavirenz; 8,14-diOH-EFV, 8,14-dihydroxy-efavirenz; 
EFV, efavirenz;  
	
	
It is well known that covalent modifications negatively impact structure and/or function of 
proteins and thereby interfere with energy metabolism, axonal transport or presynaptic 
neurotransmitter release. Therefore, protein adducts are involved in primary pathophysiological 
brain processes (Asanuma et al., 2003; Lopachin and Decaprio, 2005). Moreover, the main 
targets of these reactive metabolites are cysteine residues within proteins, which have a 
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sulfhydryl/thiol group (-SH) (Dickinson and Forman, 2002), and the redox status of brain thiols 
is determinant for neurotransmission (LoPachin and Barber, 2006).  
 
Thiols with high nucleophilic reactivity are found in diverse synaptic proteins (Fig. 4). Briefly, 
during a synapse, the action potential in the presynaptic nerve depolarizes the presynaptic 
membrane, opening the voltage-gated Ca2+ channels. The rise of Ca2+ causes the fusion of the 
plasma membrane with the transmitter-filled synaptic vesicle, followed by the release of 
neurotransmitter into the synaptic cleft by exocytosis. The transmitter molecules diffuse across 
the synaptic cleft, bind to the receptor in the postsynaptic membrane and thus modulate the 
excitability of the cell. On the presynaptic membrane occurs the retrieval of the synaptic vesicle 
by endocytosis and the refill of the vesicle with neurotransmitters (Siegel et al., 2006). In this 
process many critical steps exist (e.g., ligand-gated ion flux, receptor binding, membrane 
fusion, presynaptic release of neurotransmitter) that are influenced by the redox state of the 
sulfhydryl groups (Barber and LoPachin, 2004). In the case of presynaptic release of 
neurotransmitters, the neural soluble N-ethylmaleimide-sensitive factor attachment protein 
receptor (SNARE) complex (involved in the vesicle-membrane fusion (Sudhof and Rizo, 
2011)) and the N-ethylmaleimide-sensitive fusion (NSF, involved in the dissociation of 
SNARE after vesicle fusion (Whiteheart et al., 2001)) are cysteine rich. In fact, through mass 
spectrometry analysis, the formation of acrylamide adducts with NSF was observed, which 
might be responsible for reduced NSF activity and synaptosomal neurotransmitter release, and 
increased SNARE complex in acrylamide exposed synaptosomes (Barber and LoPachin, 2004). 
The vulnerability of synapses to toxicants action is also related to a higher rate of NO 
modulation and relatively slow turnover of NO in neuronal tissue (Esplugues, 2002). 
Additionally, the nerve terminal lacks the ability to initiate transcription based cytoprotective 
responses (LoPachin and Barber, 2006).  
 
 
Figure 4. Cysteine sulfhydryl groups of synaptic proteins and synaptic activity regulation.  




Thiols have important roles in metabolism and homeostasis of the biological systems, as the 
maintenance of the antioxidant system and in the detoxification of several molecules and 
xenobiotics (Bald et al., 2004; Prakash et al., 2009). Also, most protein thiols have 
non-catalytic functions, such as regulation of protein activity or protein folding (Jacob et al., 
2003). Both redox signaling and sulfhydryl homeostasis are important features in the context 
of brain diseases (Sabens Liedhegner et al., 2012). 
The –SH group exist in low molecular weight thiols (LMWT), e.g., as glutathione, and in 
cysteine residues of proteins (Dickinson and Forman, 2002). LMWT can be found in their free 
reduced form (RSH) (e.g., glutathione (GSH), its precursor cysteine (CysSH), and its product 
of degradation cysteinylglicine (CysGlySH)) and as disulfides (RSSR). This latter form include 
homodisulfides, formed between two identical thiols (e.g., cystine (CysSSCys), glutathione 
disulfide (GSSG)) and heterodisulfides/mixed disulfides, formed between two different thiols  
(Rossi et al., 2009). GSH is the major non-protein thiol involved in antioxidant defenses and 
its redox status is critical for a variety of biological process including cell regulation, 
inflammation, and apoptosis (Bojes et al., 1999; Rahman and MacNee, 2000; Guoyao Wu et 
al., 2004).  
Protein thiols include the sulfhydryl groups of cysteine and protein mixed disulfides with thiols 
as cysteinylglycine (protein cysteineglicinylation, PSSCysGly), cysteine (protein 
cysteinylation, CysSSP) and glutathione (protein glutathionylation GSSP), referred as protein 
S-thiolation (RSSP) (Eaton, 2006). The largest pool of LMWT in human plasma is the 
CysSH)/CysSSCys redox couple while in cells is GSH, mainly in its reduced form (Rossi et 
al., 2009). Therefore, S-glutathionylation occurs mainly in intracellular proteins whereas S-
cysteinylation is predominantly in the extracellular compartments (Rossi et al., 2009). In human 
plasma, the concentration of protein sulfhydryl groups is much higher (mM range) than LMWT 
(µM range) (Mansoor et al., 1992; Giustarini et al., 2006).  Protein S-thiolation can be 
reversible or irreversible; both cases are associated with important biological functions and 
brain pathological states (Cooper et al., 2011). Several factors can influence this linkage; from 
the enzymes involved e.g. glutaredoxin enzymes (Dalle-Donne et al., 2009) or glutathione S-
transferases (GST) ( which can also be glutathionylated) (Townsend et al., 2009) to the 
accessibility of cysteine residues (Newman et al., 2007). It is not completely understood if this 
modification serves for the activation of oxidative sensitive signaling pathways (Dalle-Donne 
et al., 2003; Baty et al., 2005) and/or as an adaptive protection response from irreversible 
oxidation of thiol groups of cysteine residues (Seres et al., 1996; Grant et al., 1999; Dalle-






The results of this thesis and their discussion are divided in three chapters. Chapter 1 comprises 
the results from the clinical study performed in HIV-infected individuals. This chapter is an 
original article published in Toxicology Letters. In Chapter 2 are presented the results 
regarding the study of time- and tissue-dependence of EFV biotransformation, performed in an 
animal model. This chapter is submitted for publication. Chapter 3 contains the results 
regarding neurological, histological and molecular evaluation performed in an animal model 
long-term exposed to EFV. This last chapter is being prepared for publication. Lastly, it is 















































GENERAL AND SPECIFIC AIMS  
	
 
Which were the main five facts that represented the starting points for our study design? 
1. Despite the correlation between EFV and CNS adverse reactions was consolidated for 
a long time, the mechanisms underlying these events were yet to be elucidated;  
2. These neuro-adverse reactions are variable among patients in type, severity, time of 
onset and persistence.   
3. EFV clearance is highly variable among patients and higher EFV concentrations were 
related with EFV neuro-adverse reactions. Nonetheless, the benefit of therapeutic drug 
monitoring and dose adjustment for the minimization of neuro-adverse reactions was 
not consensual. 
4. CYP2B6 polymorphisms are associated to high inter-patient variability in EFV 
clearance. The 8-OH-EFV is the main Phase I metabolite generated through CYP2B6 
activity. 
5. There was a demand for a suitable animal model that could allow to understand the 
mechanisms underlying EFV-CNS adverse reactions.  
 
 
Facing these facts, the general aim of this thesis was to study EFV biotransformation as an 
upstream event of the mechanisms underlying EFV-induced CNS adverse reactions. 
Additionally, it was aimed to identify mechanistically oriented markers of EFV-CNS adverse 
reactions that allow neurotoxicity risk assessment as well as the evaluation of strategies for the 
optimization of EFV use. 
To achieve these aims a translational approach was carried out by performing a clinical study 
with HIV-infected patients on EFV and an in vivo animal model of Wistar rats exposed to EFV. 
 
The specific aims of the present work are the following: 
 
1. Develop and validate a method for the quantification of EFV and its main metabolite;  
2. Measure 8-OH-EFV plasma concentrations and phenotype CYP2B6 activity in a case-
control study of HIV-infected patients on long-term combined antiretroviral therapy-
containing EFV with or without mood changes; 
3. Investigate the time-dependency of EFV biotransformation via CYP2B6 activity in 
Wistar rats with short (10 days) and long (36 days)-term EFV exposure;  
4. Explore the tissue-dependency of EFV biotransformation via CYP2B6 activity, 
comparing two brain areas (prefrontal cortex and hippocampus) with the liver; 
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5. Determine EFV-induced short- and long-term oxidative stress-related thiolomic 
signature and its tissue-dependence; 
6. Investigate the behavioral phenotype of Wistar rats exposed to long-term EFV; 
7. Compare prefrontal cortex and hippocampus histological changes, synaptic and 





















Chapter 1                                                                                     
Efavirenz biotransformation as an up-stream event 













EFV is a drug of choice for adults and children infected with the human immunodeficiency 
virus. Notably, up to 35% of patients on EFV suffer from mood changes.  
This work aimed to investigate EFV biotransformation into 8-OH-EFV as an up-stream event 
of mood changes and to evaluate the suitability of 8-OH-EFV biomonitoring for the 
minimization of these manifestations. A case-control study with two age-matched groups of 
HIV-infected male patients was performed in a group without adverse central nervous system 
complaints (28 patients) and a group presenting mood changes (14 patients). The plasma 
concentration of non-conjugated 8-OH-EFV was higher in patients with mood changes 
(p=0.020). An association between EFV and 8-OH-EFV-Glc was found (Spearman r=0.414, 
p<0.010), only within therapeutic EFV concentrations. This correlation was not observed in 
patients with toxic (> 4 mg/L) plasma concentrations of the parent drug. We conclude that 
metabolism to 8-OH-EFV is associated with EFV-related mood changes, which suggests that 
the concentration of this metabolite is a suitable parameter for therapeutic drug monitoring 
aimed at controlling these manifestations. Moreover, our data suggest that 8-OH-EFV is able 
to cross the blood-brain barrier and that the peripheral detoxification of 8-OH-EFV by 
glucuronidation may be inhibited by toxic EFV concentrations. 
 
 
1.2 MATERIALS AND METHODS  
 
1.2.1 Patients  
	
The study protocol received prior approval from the Ethics Committee of Centro Hospitalar de 
Lisboa Central, EPE (115/2013). Patients gave their written informed consent in accordance 
with the Declaration of Helsinki (attachment #1).  Compliance was controlled by the clinician.  
All patients were male adults, with documented HIV-infection, on EFV-containing cART 
(600 mg once daily) for at least one month prior to the study and regardless of past therapeutic 
history. Patients that fulfilled the inclusion criteria were sequentially included during 12 
months. Whenever present, the psychiatric effects including mood changes (anxiety, agitation, 
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euphoria, mental confusion, paranoia, hallucinations, and/or depression) were recorded 
according to the evaluation by the clinician in charge and the self-reported complaints made by 
the patients. For each EFV-treated patient with mood changes (study group, 14 patients) two 
age-matched EFV-treated patients without any CNS complaints were selected (control group, 
28 patients). Exclusion criteria were having AIDS-defining conditions and compliance issues. 
The following data were also gathered for each patient: age, time on EFV-containing cART, 
antiretroviral co-medication, time between blood sampling and last EFV dose intake, viral load, 
CD4+ T-cell count (attachment #2). 
Blood samples (2 mL) were collected into ethylenediaminetetraacetic acid (EDTA)-containing 
tubes. Plasma was obtained by centrifugation at 3000 g for 10 min, at 4 ºC.  Samples were 
stored at -80 ºC until further analysis. 
 
 
1.2.2 High performance liquid chromatography method: development 




EFV was kindly provided by Dr. Frederick A. Beland (National Center for Toxicological 
Research, Arkansas, USA). The 8-OH-EFV and 7-OH-EFV metabolites were synthesized as 
described previously (Harjivan et al., 2014). The 8,14-diOH-EFV metabolite was obtained 
from Toronto Research Chemicals Inc. (Canada). The pure compounds used for method 
interference screening were obtained from the NIH AIDS Reagent Program (Protocol 
PT090513.01). Rifampicin was kindly supplied by Aventis Pharma (Mem Martins, Portugal). 
β-Glucuronidase (Type VII-A from E.coli, E.C. 3.2.1.31, 1000 U/mL) was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). n-Hexane, acetonitrile, methanol, tert-butyl methyl ether 
and  sodium acetate were supplied by VWR (Belgium). Formic acid was purchased from Carlo 
Erba (Milano, Italy). Calibrants and quality control samples were prepared using a pool of 
plasma from healthy volunteers provided by Instituto Português do Sangue, Lisbon, Portugal, 
under protocol FCM/IPS-P-0207/CD/3HT/sr.  
 
 
1.2.2.2 Stock solutions, standard solutions and sample pre-treatment 
	
Calibration standards (CSs) were prepared by successive dilutions to obtain eight different 




Quality control (QC) samples were prepared from a distinct stock solution by successive 
dilutions to obtain final concentrations in plasma of 5, 1.5, and 0.25 mg/L (QC1, QC2, QC3, 
respectively) for EFV and 5, 2.5, and 1.5 mg/L (QC1, QC2, QC3) for 8-OH-EFV.  
Aliquots of plasma samples from patients, CSs and QCs (600 µL) were heated at 60 oC for 60 
min, for virus inactivation, before handling at room temperature and then 2 mL sodium acetate 
(0.2 M, pH 6.8) was added. One aliquot was treated with β-glucuronidase (60 µL, 1000 U/mL) 
and the other without the enzyme (60 µL of deionized ultrapure water) and both were incubated 
at 37 oC, for 60 min. Analytes were extracted with 7.5 mL of tert-butyl methyl ether and the 
organic phase was isolated and dried under vacuum (-80 kPa, at 60 ⁰C). The dried residue was 
reconstituted in 200 µL of acetonitrile: 0.1% formic acid buffer (1:1) plus 2 mL n-hexane and 
the mixture was homogenized and centrifuged. The aqueous phase was analyzed by high 
performance liquid chromatography (HPLC).   
	
	
1.2.2.3 High-performance liquid chromatography  
	
The separation of the analytes by HPLC was performed on an Agilent 1100 Series equipment 
(Agilent Technologies, Santa Clara, CA, USA), using a reversed-phase Luna C18 column (250 
mm ×4.6 mm; 5 µm; 100 Å; Phenomenex, Torrance, CA, USA). The mobile phase consisted 
of 0.1% formic acid buffer (pH 2.65) (A, 65%) and acetonitrile (B; 35%), delivered at a flow 
rate of 1.2 mL/min for the first 5 minutes. Then the percentage of solution A was gradually 
decreased to 55% for 10 min and maintained at this value for a period of 16 minutes. Finally, 
this percentage was gradually diminished to 49% during 5 minutes and maintained for the 
subsequent 7 minutes.  The column temperature was set to 30 °C, the injection volume was 100 
µL, and ultraviolet (UV) absorbance was monitored at 246 nm. 
 
 
1.2.2.4 Method validation 
	
The linearity, lower limit of quantification (LLOQ), carry-over effect, accuracy, intra- and 
inter-assay precision, and recovery of the method, as well as the stability of samples after two 
sequential freezing cycles at -80 ºC, were evaluated.  The validation criteria followed standard 
procedures for bioanalytical methods (European Medicines Agency, 2011; Services, 2013).  
The interference of plasma compounds, 7-OH-EFV and 8,14-diOH-EFV, and other 
antiretroviral drugs (abacavir, atazanavir, darunavir, emtricitabine, lamivudine, lopinavir, 
raltegravir, ritonavir, saquinavir, tenofovir and zidovudine) with EFV and 8-OH-EFV was also 
Chapter 1 
	 32	
evaluated. Due to the common co-administration with antiretrovirals, the interference of the 
anti-tuberculosis drug rifampicin was also assessed.  
 
	
1.2.3 Data analysis 
 
Systemic exposure to EFV and 8-OH-EFV was assessed in terms of absolute concentrations 
and metabolite ratios. The concentrations of 8-OH-EFV-Glc (expressed in mg/mL) were 
calculated as the difference between the analyte concentrations obtained with and without 
β-glucuronidase treatment, corrected for the molecular weight change upon conjugation.  
Statistical analysis was performed using Graph Prism® 5.0 (GraphPad Software Inc., San 
Diego, CA, USA). Data were expressed as the mean ± standard error of the mean (SEM), 
median (interquartile range; IQR), percentage or coefficient of variation (CV), whenever 
applicable. To test normality among groups, the Shapiro-Wilk test was used. The comparisons 
between the groups were performed using the Mann Whitney test. The F-test was used to 





1.3.1 Method Validation 
 
Under our HPLC conditions, 8-OH-EFV (eluting at 30 minutes) and EFV (eluting at 
41 minutes) were well separated (not shown). With the exception of lopinavir, which co-eluted 
with EFV, no interference from the other tested drugs was observed at the retention times of 
EFV or any of its metabolites. This did not affect our measurements, since none of the patients 
included in the study were on lopinavir-containing cART. 
The evaluation of linearity was performed using CSs ranging from 0.25 to 10 mg/L for 
8-OH-EFV and from 0.1 to 10 to mg/L for EFV. The linear regression model showed to be the 
most suitable for fitting a function to the experimental data (Run Test p > 0.05). The 
concentration of the standard samples significantly influenced the chromatographic signal area 
(F tests p < 0.001) for the two analytes. The correlation coefficient was > 0.99 for both 8-OH-
EFV and EFV. For the calibration curves of both analytes, the 95% confidence interval for the 




expected theoretical values at each tested concentration and presented differences lower than 
12% for both analytes.  
The intra- and interassays of multiple measures of each standard showed a CV lower than 11% 
for both EFV and 8-OH-EFV.  
The LLOQ of the method was 0.1 mg/L for EFV and 0.25 mg/L for 8-OH-EFV and no carry-
over effect or significant deviation from the nominal concentration after two freezing cycles 
were observed. 
For both analytes, the accuracy ranged between 89-101%, the intra- and interassay precision 





A total of 42 male patients (14 with mood changes) were included in the study. The most 
prevalent mood change was anxiety, in 71% of the patients.  
Anthropometric and clinical data of the patients are presented in Table 1. There were no 
differences between groups regarding race, age, time on EFV and time between sampling and 
last EFV intake.  The patients had no detectable viral load and their immunologic (CD4+ T cell 
counts) and hepatic condition (alanine aminotransferase) did not differ between groups. 
Hepatitis C co-infection occurred in three patients from the control group. Smoking and 

















Table 1. Anthropometric and clinical data. 
 
Control group: HIV-treated patients without any CNS complaint; Study group: HIV-treated patients presenting 
mood changes. Data are presented as median (IQR) or number (%). a χ2 test. b Mann–Whitney-U-test. ALT, alanine 
aminotransferase; EFV, efavirenz; ns, not significant. 
 
 
The plasma concentrations of EFV, 8-OH-EFV, and 8-OH-EFV-Glc are presented in Table 2. 
No differences between groups were found in EFV levels. Two patients from the control group 
and one from the study group had EFV concentrations higher than 4 mg/L, the proposed 
minimal toxic concentration (Marzolini et al., 2001).  
 
Patients with mood changes had higher plasma concentrations of 8-OH-EFV than those in the 
control group and this represented the only significant difference in analyte levels found 
between groups. The 8-OH-EFV/EFV ratio tended to be higher in the study group, although 
the difference did not reach statistical significance.  
The major metabolite found in circulation was 8-OH-EFV-Glc in both groups. Its concentration 






Parameter Control Group Study Group p 
value 
Number of patients 28 14  
Non-Caucasians (%) 14 7 ns a 




No 46 69 ns a 
Social 32 23 ns a 
Chronic 21 8 ns a 
Smokers (%) 50 31 ns a 
Time on EFV (years) 4 (2 - 7) 5 (2 - 10) ns b 
CD4+ T-cell count (cells/mm3) 626 (494 - 798) 610 (464 - 778) ns b 
ALT (U/L) 29 (20 - 39) 27 (19 - 38) ns b 
Time between sampling and last EFV 
intake (h) 





Table 2. Plasma concentrations of efavirenz, 8-hydroxy-efavirenz and 
8-hydroxy-efavirenz-glucuronide. 
Analyte Control Group 28 patients 
       Study Group 
            14 patients 
p 
value 
EFV (mg/L)         1.55 (1.38 - 2.11) 1.88 (1.50 - 3.11) ns 
8-OH-EFV (mg/L)         1.04 (0.80 - 1.69) 1.69 (1.03 - 3.19) 0.020 
8-OH-EFV-Glc (mg/L)         11.74 (6.15 - 14.05) 13.85 (9.17 - 27) ns 
8-OH-EFV/EFV         0.68 (0.40 - 0.92) 0.81 (0.31 - 1.84) ns 
 
Control group: HIV-treated patients without any CNS complain; Study group: HIV-treated patients 
presenting mood changes. Data are presented as median (IQR). Mann–Whitney U-test. EFV, efavirenz; 
8-OH-EFV, 8-hydroxy-efavirenz; 8-OH-EFV-Glc, 8-hydroxy-efavirenz-glucuronide; ns, not 
significant.   
 
We found that the 8-OH-EFV and EFV concentrations were not related. Conversely, within the 
therapeutic range of EFV concentrations (1 - 4 mg/L) (Marzolini et al., 2001) the present data 
indicate a positive association between the concentrations of 8-OH-EFV-Glc and EFV 
(Spearman r = 0.414, p < 0.010) (Fig. 5). This correlation was not observed at toxic (> 4 mg/L) 
concentrations of EFV (Fig. 5). 
 
	
Figure 5. Correlation between EFV and 8-OH-EFV-Glc. EFV plasma concentration is associated with 
8-OH-EFV-Glc plasma concentration (Spearman r = 0.414, p = 0.010, n=39) at non-toxic EFV levels. 
This association was not observed for patients with EFV concentrations higher than minimal toxic EFV 
concentration (4 mg/L). EFV, efavirenz; 8-OH-EFV-Glc, 8-hydroxy-efavirenz-glucuronide. Open 
circles: patients with therapeutic EFV concentrations; Full circles: patients with toxic (> 4 mg/L) EFV 





This work was aimed at evaluating the plasma concentrations of EFV and its metabolites, 
8-OH-EFV and 8-OH-EFV-Glc, in a case-control study comparing HIV-infected male patients 
with or without mood changes complaints. Herein we have demonstrated the feasibility of using 
this straightforward methodology, rather than more expensive and elaborate liquid-
chromatography-mass spectrometry approaches, to monitor EFV and 8-OH-EFV at clinically 
relevant levels. 
Literature data reporting the dependence of CNS adverse reactions on EFV concentration are 
contradictory (Ngaimisi et al., 2010; Cho et al., 2011; Habtewold et al., 2011; Tovar-y-Romo 
et al., 2012; Aouri et al., 2016). This is probably due to the high inter-individual PK variability 
of EFV (Pereira et al., 2008), which is largely attributed to its biotransformation (Marzolini et 
al., 2001; Fumaz et al., 2005; Pereira et al., 2008;Tashima et al., 2008; van Luin et al., 2009b; 
Kenedi and Goforth, 2011; Pereira et al., 2012; Apostolova et al., 2015b; Winston et al., 2015; 
Aouri et al., 2016). The discrepant data reported might also reflect the broad type of symptoms 
considered. Moreover, literature data on relationships between EFV metabolites and a 
particular group of CNS manifestations have yet to be provided (Winston et al., 2015; Aouri et 
al., 2016). These uncertainties prompted us to investigate EFV-induced mood changes. 
The most frequent mood change recorded in our study group was anxiety, which is in agreement 
with previously reported clinical studies (Fumaz et al., 2002; Fumaz et al., 2005; Rihs et al., 
2006). This is also in line with data reporting an anxiogenic effect in male CF-1 mice upon 
chronic exposure to EFV (Romao et al., 2011). Additionally, our results suggest that mood 
changes are related with plasmatic concentrations of 8-OH-EFV. This contrasts with the lack 
of consistent correlations reported in the literature, which might be a reflection of our effort to 
eliminate potential variability factors from the current study (e.g., type of CNS effect, the time 
on EFV, PK parameter and sex). 
EFV is a moderate inducer of CYP2B6 (U.S. Food and Drug Administration, 2012), the major 
isoform responsible for the formation of 8-OH-EFV. The drug has a long-term auto-induction 
effect that is dose-, duration of treatment- and genetically-dependent, resulting in lower EFV 
plasma concentrations after multiple dosing (Ngaimisi et al., 2010; Habtewold et al., 2011). 
Previous studies have shown that the proportion of patients with EFV concentrations higher 
than 4 mg/mL, which is considered a neurotoxic concentration (Marzolini et al., 2001), 
decreased by 44% from week 4 to week 16 of therapy, due to auto-induction of EFV 
metabolism (Ngaimisi et al., 2010). Accordingly, the concentration of 8-OH-EFV was much 
higher in week 16 than week 4, showing an accumulation of 8-OH-EFV in the first months of 




EFV differs between EFV-induced short- and long-term effects. While short-term effects would 
probably be more dependent on EFV concentration, long-term adverse reactions will probably 
be more related to 8-OH-EFV accumulation. This is in accordance with the fact that the 
majority of EFV-induced adverse CNS reactions is reversible and tends to occur during the first 
weeks of treatment (Fumaz et al., 2005), when the auto-induction period of EFV 
biotransformation is starting (Ngaimisi et al., 2010). After this period, the plasmatic 
concentrations of EFV are considerably lower (Ngaimisi et al., 2010) and have low intra-
individual variability (Pereira et al., 2008). One major difference between our study and others 
is the time on EFV.  In fact, in the few studies mentioning the time on EFV, metabolites were 
quantified during the first 16 weeks (Ngaimisi et al., 2010; Cho et al., 2011; Habtewold et al., 
2011). As this corresponds to the auto-induction period, the maximum levels of metabolites 
were not attained and adverse reactions are likely to have been mainly EFV-dependent. By 
contrast, all patients in our study were users of EFV-containing cART beyond the 
auto-induction stage and time on EFV did not differ between control and study groups. 
Accordingly, the EFV concentration was similar in the two groups but differences were 
observed in the levels of 8-OH-EFV. Taken together, these data demonstrate the need to include 
time of exposure to EFV in neuro-safety evaluation studies. In fact, Leutscher et al. (2013) 
suggested that EFV discontinuation occurs late in the course of treatment due to the persistence 
of CNS toxicity, which may impact quality of life negatively on a long-term basis. Herein, we 
present convincing data that patients on EFV for a long period show anxiety. Actually, our data 
emphasize the relevance of the 8-OH-EFV metabolite, rather than EFV, when a persistent CNS 
effect is considered. While the EFV concentration remains stable after the first year, the 
documented variability during the auto-induction period supports the need for therapeutic drug 
monitoring based on quarterly sampling in the first year of therapy (Pereira et al., 2008). It 
remains to be established if this is also applicable to 8-OH-EFV.  
Induction-driven changes in the levels of EFV and its metabolites differ between women and 
men (Habtewold et al., 2011) and this might explain conflicting literature results, depending on 
the number of women included in the studies. To reduce sex-related confounding factors, all 
patients in our study were men, which differs greatly from other studies in which the percentage 
of males varied from 20 to 80% (Ngaimisi et al., 2010; Cho et al., 2011; Habtewold et al., 
2011; Tovar-y-Romo et al., 2012). 
Our data support a role for 8-OH-EFV in the genesis of mood changes in patients on long-term 
EFV exposure. This suggests that the plasma concentration of 8-OH-EFV may be more 
appropriate than EFV levels for therapeutic drug monitoring towards the minimization of these 
CNS effects. Nonetheless, this raises an interesting question: if mood changes are dependent 
on EFV biotransformation and EFV predominantly undergoes hepatic clearance, why is the 
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CNS compartment a vulnerable milieu for EFV toxicity? Several factors can be invoked to 
explain this apparently conflicting scenario, namely the fact that EFV tends to accumulate in 
the CNS compartment (Decloedt et al., 2015). Indeed, although EFV is highly protein-bound, 
the CSF penetration of unbound EFV is high (Yilmaz et al., 2012; Avery et al., 2013a; 
Thompson et al., 2015) and the drug is not actively cleared from the CNS (Decloedt et al., 
2015). One additional potential key player is the fact that EFV is a substrate for CYP2B6 (U.S. 
Food and Drug Administration, 2012), the major isoform responsible for its metabolic 
conversion into 8-OH-EFV. Whereas CYP2B6 is abundant in the liver, it is also expressed in 
the brain, albeit at much lower levels (Miksys and Tyndale, 2013), and its expression can vary 
by more than two-fold across brain areas (Miksys et al., 2003). The concentration of this 
isoform in specific regions and cell types may originate particular biotransformation 
environments (Miksys et al., 2000; Miksys et al., 2003), plausibly predisposed to local 
accumulation of 8-OH-EFV. The non-CYP2B6-mediated metabolic pathways of EFV are 
diminished in the brain, namely the minor phase I formation of 7-OH-EFV via CYP2A6 
(Dutheil et al., 2009) as well as phase II metabolism (Ouzzine et al., 2014) (Fig. 4), which can 
also contribute to 8-OH-EFV accumulation. Once in the brain, the formation of electrophilic 
quinone and quinone-imine species upon oxidation of 8-OH-EFV is a conceivable event 
(Harjivan et al., 2014), similarly to what happens with endogenous neurotoxins (Baumgarten 
and Lachenmayer, 2004; Kato et al., 2012; Kato et al., 2014). Quinone and quinone-imine 
metabolites have a recognized toxicological relevance, not only due to their ability to generate 
reactive oxygen species but also to their capacity to yield covalent adducts with proteins (Bolton 
et al., 2000; Monks and Jones, 2002). In fact, the formation of these reactive metabolites may 
be at the genesis of CNS effects by distinct but not mutually exclusive mechanisms. For 
instance, adduct formation could negatively impact the function of proteins and thereby 
interfere with energy metabolism, axonal transport or pre-synaptic neurotransmitter release 
(Asanuma et al., 2003; Lopachin and Decaprio, 2005). Moreover, electrophilic species have 
the ability to reduce glutathione (GSH) content (Rabinovic and Hastings, 1998), which has been 
described in several psychiatric conditions (Eskiocak et al., 2005; Gawryluk et al., 2011). The 
brain is highly susceptible to oxidation, due to its high oxygen consumption rate, and has low 
levels of GSH, when compared to other tissues (Ballatori et al., 2009). Thus, depletion of brain 
GSH levels may be critical since this molecule is not only an antioxidant but also plays key 
roles as neuromodulator, neurotransmitter, and enabler of brain cells’ survival (Ballatori et al., 
2009; G. Morris et al., 2014).  
Our observation of higher plasma concentrations of 8-OH-EFV in the study group suggests that 
peripheral 8-OH-EFV contributes to the brain pool of this toxic metabolite. Although the ability 
of 8-OH-EFV to cross the blood-brain barrier has yet to be demonstrated, our results appear 




One additional important observation was the trend for a higher 8-OH-EFV/EFV ratio in the 
study group compared to the control group, albeit not reaching statistical significance. This 
observation, together with the higher concentrations of 8-OH-EFV in the study group, suggests 
that this group of patients had a higher CYP2B6 activity than the control group. In fact, the 8-
OH-EFV/EFV ratio has been considered a metabolic phenotype for CYP2B6 activity (U. S. 
Food and Drug Administration, 2014). This is an important finding since the metabolic 
phenotype is central to clinical implementation and monitoring in pharmacovigilance 
throughout the study of PK drug-drug interactions and individualization of drug dosages 
(Llerena and Penas-Lledo, 2015). In this regard, it is noteworthy that brain CYP2B6 will not 
only metabolize EFV to 8-OH-EFV but also influence the levels of endogenous metabolites 
such as mood-related steroids and neurotransmitters (e.g., testosterone (Imaoka et al., 1996; 
Fink et al., 1999), and serotonin (Fradette et al., 2004).  
It is also noteworthy that the plasma concentrations of 8-OH-EFV-Glc were similar in both 
groups and much higher than the levels of 8-OH-EFV. Taking into consideration that, as 
opposed to 8-OH-EFV, the glucuronide cannot be metabolized to toxic electrophiles, this 
observation suggests that phase II glucuronidation is the main route of 8-OH-EFV 
detoxification. Thus, controversies regarding PK-neurosafety relationships between studies on 
EFV may result from the fact that these studies typically considered the total 8-OH-EFV 
concentrations (i.e., 8-OH-EFV plus 8-OH-EFV-Glc) and no correlations were established with 
the non-conjugated metabolite per se. Toxic EFV concentrations (> 4 mg/L) (Marzolini et al., 
2001) were herein associated with lower 8-OH-EFV-Glc concentrations. This suggests that 
higher EFV concentrations are able to inhibit UGT enzymes, which is in line with in vitro data 
(Belanger et al., 2009; Ji et al., 2012). In fact, EFV is reported as a non-competitive inhibitor 
of UGT1A1 and a competitive inhibitor of UGT1A9 (Ji et al., 2012) and both isoforms 
participate in 8-OH-EFV-Glc formation (Bae et al., 2011). This inhibition may represent a new 
toxicity mechanism at high EFV concentrations. Indeed, the diminished peripheral 
detoxification of 8-OH-EFV under these conditions suggests a synergistic effect of EFV on the 
toxic events induced by its major metabolite. Figure 6 illustrates the different mechanistic 
hypotheses described for EFV-neurotoxicity (O'Mahony et al., 2005; Streck et al., 2008; 
Apostolova et al., 2010; Tovar-y-Romo et al., 2012; Brandmann et al., 2013; Blas-Garcia et 
al., 2014; Brown et al., 2014; de Oliveira et al., 2014; Funes et al., 2014; Apostolova et al., 







Figure 6. Schematic representation of the events preceding mood changes upon EFV exposure. Upstream events: in the liver, EFV is mainly metabolized via CYP2B6 to 
8-OH-EFV, to a slighter degree to 7-OH-EFV via CYP2A6 and barely conjugated by UGT2B7 to EFV-Glc. The hydroxylated metabolites undergo phase II conjugation through 
glucuronidation (major) and sulfonation (minor). Formation of 8-OH-EFV may occur to a lesser extent in the brain and further oxidation can generate a reactive quinoid 
metabolite, ultimately leading to detrimental ROS generation, GSH depletion and protein modification that may result in downstream neurotoxicity. EFV, efavirenz; 8-OH-
EFV, 8-hydroxy-efavirenz; 7-OH-EFV, 7-hydroxy-efavirenz; EFV-Glc , efavirenz- glucuronide; 8-OH-EFV-Glc, 8-hydroxy-efavirenz-glucuronide; 7-OH-EFV- Glc, 7-
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Time-Course of efavirenz biotransformation: a 














EFV is an anti-HIV drug that presents relevant short- and long-term central nervous system 
adverse reactions. Its main metabolite (8-OH-EFV) was demonstrated to be a more potent 
neurotoxin than EFV itself. This work was aimed to understand how EFV biotransformation to 
8-OH-EFV is related to its short- and long-term neuro-adverse reactions. To access those 
mechanisms, the expression and activity of Cyp2b enzymes as well as the thiolomic signature 
(low molecular weight thiols plus S-thiolated proteins) were longitudinally evaluated in the 
hepatic and brain tissues of rats exposed to EFV during 10 and 36 days. EFV and 8-OH-EFV 
plasma concentrations were monitored at the same time points. Cyp2b induction had a delayed 
onset in liver (p<0.001), translating into increases in Cyp2b activity in liver and 8-hydroxy-
efavirenz plasma concentration (p<0.001). Moreover, an increase in S-cysteinylglycinylated 
proteins (p<0.001) and in free low molecular weight thiols was also observed in liver. A distinct 
scenario was observed in hippocampus, which showed an underexpression of Cyp2b as well as 
a decrease in S-cysteinylated and S-glutathionylated proteins. Additionally, the observed 
changes in tissues were associated with a marked increase of S-glutathionylation in plasma. 
Our data suggest that the time course of EFV biotransformation results from different 
mechanisms for its short- and long-term neurotoxicity. The difference in the redox profile 
between liver and hippocampus might explain why, despite being mostly metabolized by the 
liver, this drug is neurotoxic. If translated to clinical practice, this evidence will have important 
implications in EFV short- and long-term neurotoxicity prevention and management. 
 
 
2.2 MATERIALS AND METHODS  
 
2.2.1 Drugs and Chemicals  
	
EFV was kindly provided by Dr. Frederick A. Beland (National Center for Toxicological 
Research, Arkansas, USA). HPLC-grade solvents were purchased from VWR (Belgium). β-
Glucuronidase (Type VII-A from E.coli, E.C. 3.2.1.31, 1000 U/mL), Arylsulfatase (Type H-1, 
from E. coli, E.C. 3.1.6.1., 1000 U/mL) and reagents used for thiolomic profile determination 
were purchased from Sigma-Aldrich (USA), with the exception of trichloroacetic acid (TCA), 
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which was purchased from Roth (Germany). A kit from NZYTech (Portugal) was used for the 
cDNA synthesis. Primers and PowerUp™ SYBR® Green Master Mix used for quantitative real 





Experiments were performed with male Wistar rats (Rattus norvegicus L.), aged 13 weeks, with 
a mean body weight of 293 ± 60 g, obtained from the NOVA Medical School animal facility. 
Animals were housed two per cage in polycarbonate cages with wire lids (Tecniplast, Italy), 
under 12 h light/dark cycles (8 am - 8 pm), at room temperature (22 ± 2.0 °C) and a relative 
humidity of 60 ± 10%. Rats were maintained on a standard laboratory diet (SDS RM1, Special 
Diets Services, UK) and ad libitum reverse osmosis water. 
Rats were randomly assigned into four groups: 10-day control (CTL), 10-day EFV-exposed, 
36-day CTL, and 36-day EFV-exposed. In order to reduce the number of animals used in the 
experiments (3Rs approach), the same rat was used for at least two experiments (i.e., one 
hippocampus was used to determine ethoxycoumarin O-deethylase (ECOD) activity and the 
other for Cyp2b expression). A number of 8 animals per group was used for thiolomic profile 
(RSSP+LMWT) analysis. For Cyp2b expression and activity analysis a number of 6 animals 
per group were used.  
NIH Principles of Laboratory Animal Care (NIH Publication 85-23, revised 1985), the 
European guidelines for the protection of animals used for scientific purposes (European Union 
Directive 2010/63/EU) and the Portuguese Law nº 113/2013 concerning ethical use of animals 
were followed. The experimental procedures (protocol nº 14/2016/CEFCM) received prior 
approval by the Institutional Ethics Committee of the NOVA Medical School for animal care 
and use in research. 
 
 
2.2.3 Experimental protocol 
	
Animals from the EFV groups were administered 9 mg/kg/day of EFV by oral gavage, 
suspended in 2 mL of reverse osmosis water, and CTL groups were administered the same 
volume of reverse osmosis water. The administrations were performed using a sterile 
polypropylene feeding tube (15 gauge; tip diameter: 3 mm; length: 78 mm; Instech 
Laboratories, Inc., USA) to reduce the risk of trauma, perforation and cross contamination 




by the same individual for a period of 2 minutes each, and accustomed to the gavage position, 
in a different animal facility room. 
The animals were weighed at baseline and twice a week during the entire study. The amounts 
of EFV were adjusted accordingly, in order to ensure a constant daily dose. EFV or vehicle 
were administered daily in the morning, at approximately the same schedule.  
At day 10 or 36, approximately 1-2 hours after EFV administration, rats were anesthetized by 
intraperitoneal injection with medetomidine (0.5 mg/kg body weight; Domitor®, Pfizer Animal 
Health) and ketamine (75 mg/kg body weight; Imalgene 1000®, Mérial, Lyon, France). 
Cardiac puncture was performed for blood sampling and the plasma samples were stored at -
80 °C until use. The animals were then decapitated under deep anesthesia, brains were 
removed from skull, and hippocampus and prefrontal cortex were dissected. The liver was 
also rapidly removed.  
 
 
2.2.4 Cyp2b1 and Cyp2b2 gene expression 
	
Liver, hippocampus and prefrontal cortex were collected and homogenized in Trizol® (Life 
Technologies) using a tissue homogenizer (Heidolph DIAX 900). Total RNA extraction was 
performed according to the Trizol® manufacturer’s instructions. The RNA concentration was 
determined prior to cDNA synthesis by measuring the absorbance at 260 nm on a 
SPECTROstar Omega spectrometer (BMG Labtech, Ortengerg, Germany) operating in the 
LVis Plate mode. cDNA was synthesized from 1 µg RNA according to the manufacturer’s 
instructions. qPCR was carried out in a final volume of 15 µL with 2× PowerUp™ SYBR® 
Green Master Mix and 0.3 µM of each primer, plus 2 µL of cDNA was added as template.  
Rat specific primers were used for the housekeeping gene ß-actin (Forward 5’-
AAGTCCCTCACCCTCCCAAAAG-3’; Reverse 5’-AAGCAATGCTGTCACCTTCCC-3’) 
(Peinnequin et al., 2004) and for the target genes Cyp2b1 (Forward 5’-
GCTCAAGTACCCCCATGTCG-3’; Reverse 5’-ATCAGTGTATGGCATTTTACTGCGG-
3’) and Cyp2b2 (Forward 5’-CTTTGCTGGCACTGAGACCG-3’; Reverse 5’- 
ATCAGTGTATGGCATTTTGGTACGA-3’) (Schilter et al., 2000). The efficiency of each 
reaction was estimated with a calibration curve built using serial cDNA dilutions (1, 10-1, and 
10-2) in order to construct a standard curve for each gene and tissue. The reaction was performed 
on an Applied Biosystems 7300 Real Time PCR System, consisting of a denaturation step at 95 
°C for 10 min followed by 40 cycles of denaturation at 95 °C for 15 seconds, annealing at 60 
°C for 1 min and extension at 72 °C for 30 seconds. A dissociation stage was added to determine 
the melting temperature (Tm) of a single nucleic acid target sequence as a quality and specificity 
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measure. The comparative Ct method (2-ΔΔCt) was used to quantify the target genes, which were 
normalized to the reference ß-actin gene, and fold change was calculated in EFV-treated rats 
relative to the respective CTL group. 
 
 
2.2.5 Determination of ethoxycoumarin-O-deethylase (ECOD) activity  
	
ECOD activity measures rat Cypla1/2, Cyp2a1, Cyp2b1/2, Cyp2c6/7, Cyp2c11, Cyp2c13, and 
Cyp2el, among which the 1a and 2b subfamilies are the most effective forms (Kern et al., 1997). 
The procedure was performed as previously described (Cipriano et al., 2016; Pinheiro et al., 
2016). Briefly, liver, hippocampus and prefrontal cortex slices were incubated for 90 min with 
7-ethoxycoumarin (0.8 mM) in Dulbecco's Modified Eagle Medium (DMEM).  The 7-
hydroxycoumarin concentrations were determined after 2 h of enzymatic digestion with a β-
glucuronidase/arylsulfatase solution (pH 4.5 in 0.1 M acetate buffer) followed by a liquid-liquid 
extraction with chloroform. The 7-hydroxycoumarin fluorescence was measured using the 
SPECTROstar Omega spectrometer (lexc 340 nm; lem 460 nm). The results are presented as the 
EFV/CTL fluorescence ratio for each tissue and exposure time. Total protein concentration was 
determined by absorbance at 280 nm using the same spectrometer in the LVis Plate mode.   
  
 
2.2.6 Determination of efavirenz and 8-hydroxy-efavirenz plasma 
concentrations 
	
EFV and 8-OH-EFV were quantified as previously described (Grilo et al, 2016). Briefly, the 
plasma samples were incubated with β-glucuronidase, at 37 ºC, for 1 h. Analytes were extracted 
with tert-butyl methyl ether and the organic phase was isolated and dried under vacuum (-80 
kPa, at 60 ºC). The dried residue was reconstituted in acetonitrile: 0.1% formic acid plus n-
hexane (50/50 v/v) and the mixture was homogenized and centrifuged. The samples were 
analyzed by HPLC on an Agilent 1100 Series equipment (Agilent Technologies, Santa Clara, 
CA, USA), using a reversed-phase Luna C18 column (250 mm ×4.6 mm; 5 µm; 100 Å; 
Phenomenex, USA). The mobile phase consisted of 0.1 % formic acid (pH 2.65) (solvent A, 
65%) and acetonitrile (solvent B, 35%) for the first 5 min, at a flow rate of 1.2 mL/min. The 
percentage of solution A was linearly decreased to 55% for 10 min and maintained at this value 




maintained for the following 7 min.  The column temperature was set at 30 °C, the injection 
volume was 100 µL, and UV absorbance was monitored at 246 nm. 
 
   
2.2.7 Determination of the thiolomic profile  
	
GSH, its precursor CysSH and its catabolism product CysGlySH were quantified. These three 
moieties were analyzed in their RSSP forms (GSSP, CysSSP and PSSCysGly) and in their 
LMWT forms. The latter were composed by the RSH fractions, including GSH, CysSH and 
CysGlySH, and the respective disulfides.  
Liver (approximately 50 mg), hippocampus (one) and prefrontal cortex (one) were collected, 
kept on ice, and immediately homogenized in 400 µL of iced phosphate-buffered saline (1x), 
using a tissue homogenizer (Heidolph DIAX 900). An initial volume of 50 µL from the tissue 
homogenate and plasma were used to assess thiol fractions. 
The total ‘thiol’ fraction (RSSP+RSH+RSSR) was obtained by reducing the sulfhydryl groups 
with tris (2-carboxyethyl)phosphine hydrochloride (TCEP; 100g/L, 5 µL). After a 30 min 
incubation at room temperature, the samples were treated with TCA (100 g/L) containing 1 
mM EDTA (45 µL) for protein precipitation. Each mixture was then centrifuged (13000 g, 10 
min, 4°C) and the supernatant collected to a new tube containing 1.55 M NaOH (5 µL), 125 
mM sodium tetraborate buffer (Na2B4O7, pH 9.5) with 4 mM EDTA (62.5 µL) and 7-
fluorobenzo-2-oxa-1,3-diazole-4-sulfonic acid ammonium (SBD-F) 1 g/L) in Na2B4O7 buffer 
(125 mM with 4 mM EDTA) (25 µL). The final mixture was vortexed and incubated in the 
dark, at 60 ºC for 1 h, to complete the derivatization of the free sulfhydryl groups. Finally, a 
volume of 10 µL was analyzed by HLPC.  
The LMWT (RSSR+ RSH) and the reduced (RSH) fractions were also analyzed. Two aliquots 
from the same sample were submitted to protein precipitation with TCA, with subsequent 
centrifugation (13000 g, 10 min, at 4ºC), as described (Przemyslaw et al., 2011). Then, while 
one aliquot was reduced with the TCEP reagent for total non-bound fraction quantification, the 
other was incubated with reverse osmosis water in order to obtain the naturally reduced RSH 
fraction. After incubation at room temperature, for 30 min, the protocol described above was 
followed. The RSSP contribution for each particular thiol was obtained by subtracting the 
LMWT (RSH+RSSR) from the total thiol concentration.	
The quantifications were performed by HPLC-FD analysis on a Shimadzu LC-10AD VP 
(Shimadzu Scientific Instruments Inc) system using a reversed-phase C18 LiChroCART 250-
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4 column (LiChrospher 100 RP-18, 5µm, VWR, USA), at 29 ºC with an adapted from the 
methodology reported by Nolin and co-authors (Nolin et al., 2007). The detector was set at 
excitation and emission wavelengths of 385 and 515 nm, respectively. The mobile phase 
consisted of 100 mM acetate buffer (pH 4.5) and methanol [99:1 (v/v)]. The analytes were 
separated in an isocratic elution mode for 20 min, at a flow rate of 0.8 mL/min. 
 
 
2.2.8 Data analysis 
 
Statistical analysis was performed using Graph Prism® 5.0 (GraphPad Software Inc., San 
Diego, CA, USA). The comparisons between groups were performed using the Unpaired t-test 







At the beginning of the experiments, the animals were age-matched and no differences were 
found regarding animal body weights. However, at the end of the 36-day period, the EFV-




2.3.2 Cyp2b expression 
 
Regardless of treatment time, liver was the tissue that presented higher expression of Cyp2b1 
upon EFV exposure (Fig. 7A). Long-term (36 days) exposure to EFV resulted in a 4-fold 
increase in liver Cyp2b1 expression compared to short-term exposure (10 days) (p<0.001). A 
similar pattern was observed for the prefrontal cortex (13-fold increase; p<0.001) while the 
hippocampus presented a decrease in Cyp2b1 expression with time (p<0.001). Expression of 
Cyp2b2 was also lower in the hippocampus, while liver and prefrontal cortex had comparable 
levels upon short-term EFV exposure (Fig. 7B). However, while time increased Cyp2b2 






Figure 7. Cyp2b1 (A) and Cyp2b2 (B) expression in liver, hippocampus and prefrontal cortex of 
rats exposed to efavirenz during 10 and 36 days. n = 6 animals per group. The data are expressed in 
fold change compared to non-treated controls. * represents time-dependent differences (Unpaired t-test, 
***p<0.001) and # represents differences among tissues using liver as control (Two-way ANOVA with 
Bonferroni post-test, ##p<0.01, ###p<0.001). 
 
	
2.3.3 Quantification of ECOD activity 
 
The tissue and time dependence of Cyp2b expression were not reflected in ECOD activity (Fig. 
6), for which an increase with the duration of EFV-exposure was only observed in the liver 
(p<0.001).  
 
Figure 8. ECOD activity in liver, hippocampus and prefrontal cortex of rats exposed to efavirenz 
during 10 and 36 days. n = 6 animals per group. Data are expressed in fold change compared to non-
treated controls. * represents time-dependent differences (Unpaired t-test, ***p<0.001) and # represents 
differences among tissues using liver expression as control (Two-way ANOVA with Bonferroni post-test, 




2.3.4 Determination of efavirenz and 8-hydroxy-efavirenz plasma 
concentrations 
	
While no differences were found for EFV plasma concentration between 10 and 36 days (Fig. 
9), the 8-OH-EFV concentrations raised over time (p=0.02) (Figure 3).   
 

















Figure 9. Efavirenz and 8-hydroxy-efavirenz quantification in rat plasma at 10 and 36 days of 
efavirenz exposure. n = 8 animals per group. Data are expressed as mean ± standard error of the mean 
in mg/L.* represents time-dependent differences (unpaired t-test, *p=0.02). 
 
 
2.3.5 Thiolomic signature  
 
No differences over time were found for any of the analytes in control animals (Table 3). With 
the exception of LMWCys, the liver presented higher levels of the analytes, when compared to 
prefrontal cortex and hippocampus at both time points. Additionally, while in the liver the 
predominant LMWT fraction was the reduced form, the oxidized form accounted for 
approximately 40% in the brain.  
 
Regarding differences in EFV-treated animals, the liver had a general increase in all analytes 
over time (Table 4). Exceptions were the GSSP and CysSSP levels. In hippocampus, a marked 
decrease in GSSP (p<0.01) and CysSSP (p<0.001) was observed, in parallel with an increase 
in GSH concentration (p<0.001). In prefrontal cortex, both decreased CysSSP (p<0.01) and 
increased GSH synthesis (p<0.001) were observed. These variations were more modest than 
those found for hippocampus. The higher variation found in plasma was for GSSP (p<0.001), 
which increased over time in contrast to what was found for hippocampus. This increase was 























Data are presented as mean ± standard error of the mean in µM/mg tissue. n = 8 animals per group. a Time-dependent differences for each tissue (unpaired t-test); bComparison 
between liver, prefrontal cortex and hippocampus for the 10-day EFV exposure data point (one-way ANOVA ***p<0.001). LMWGSH: total non-protein bound glutathione; 
GSH: reduced glutathione; GSSP: S-glutationylated proteins; LMWCys: total non-protein bound cysteine; CysSH: reduced cysteine; CysSSP: S-cysteinylated proteins; 









10 days 36 days pa 10 days 36 days pa 10 days 36 days pa pb 
GSH 8.80±1.48 10.19±1.80 ns 1.04±0.18 1.14±0.40 ns 1.05±0.22 1.03±0.30 ns *** 
LMWGSH 10.80±1.41 11.36±1.26 ns 1.83±0.27 1.91±0.47 ns 1.79±0.25 1.86±0.49 ns *** 
GSSP 2.26±1.58 2.01±0.89 ns 0.50±0.32 0.38±0.18 ns 0.43±0.22 0.46±0.15 ns *** 
CysSH 0.17±0.04 0.17±0.05 ns 0.08±0.02 0.08±0.03 ns 0.10±0.03 0.08±0.01 ns *** 
LMWCys 0.25±0.05 0.26±0.04 ns 0.20±0.05 0.18±0.04 ns 0.23±0.04 0.20±0.03 ns ns 
CysSSP 0.22±0.09 0.21±0.05 ns 0.08±0.04 0.08±0.02 ns 0.09±0.03 0.09±0.02 ns *** 
CysGlySH 0.03±0.002 0.03±0.005 ns 0.005±0.001 0.006±0.001 ns 0.004±0.001 0.005±0.001 ns *** 
LMWCysGly 0.03±0.01 0.04±0.01 ns 0.01±0.003 0.01±0.004 ns 0.01±0.001 0.01±0.003 ns *** 
PSSCysGly 0.06±0.01 0.06±0.01 ns 0.01±0.003 0.004±0.003 ns 0.01±0.002 0.01±0.002 ns *** 
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Table 4: Evaluation of the thiolomic profile in liver, prefrontal cortex, hippocampus, and plasma of efavirenz-exposed animals at 10 and 36-days  
 
 
Data are presented as the EFV/CTL ratio (unpaired t-test, ap<0.001; bp<0.01; cp<0.05); Δ: variation in percentage of the EFV/CTL ratio between 10 and 36 days. n = 8 animals 
per group. LMWGSH: total non-protein bound glutathione; GSH: reduced glutathione; GSSP: S-glutationylated proteins; LMWCys: total non-protein bound cysteine; CysSH: 
reduced cysteine; CysSSP: S-cysteinylated proteins; LMWCysGly: total non-protein bound cysteinylglycine; CysGlySH: reduced cysteinylglycine; PSSCysGly: S-cysteinyl-
glycinylated proteins. ns: not significant. 
EFV/CTL 
 Ratio 
Liver Prefrontal cortex Hippocampus Plasma 
10 days 36 days Δ (%) 10 days 36 days Δ (%) 10 days 36 days Δ (%) 10 days 36 days Δ (%) 
GSH 0.96±0.02 1.14±0.02 18a 1.13±0.04 1.31±0.07 18a 1.21±0.04 1.58±0.10 37a 1.11±0.05 0.96±0.02 -15a 
LMWGSH  1.01±0.02 1.22±0.02 21a 1.06±0.03 1.22±0.04 16a 1.04±0.02 1.17±0.05 13a 1.02±0.02 1.00±0.03 -2 
GSSP 1.16±0.48 1.26±0.35 10 1.10±0.23 0.97±0.21 -13 1.23±0.27 0.89±0.11 -34b 0.82±0.06 1.16±0.07 34a 
CysSH 0.83±0.06 0.93±0.04 10b 0.90±0.06 0.86±0.04 -4 0.92±0.05 0.93±0.03 1 1.05±0.05 0.95±0.03 -10a 
LMWCys 0.89±0.04 1.09±0.06 21a 0.88±0.07 0.92±0.03 4 0.83±0.05 0.99±0.02 16a 1.00±0.01 1.05±0.01 5a 
CysSSP 1.42±0.20 1.48±0.15 6 0.96±0.14 0.72±0.13 -24b 1.12±0.19 0.67±0.04 -45a 1.15±0.03 1.08±0.04 -7b 
CysGlySH 0.90±0.03 1.12±0.03 22a 0.87±0.04 1.14±0.04 27a 0.95±0.02 0.91±0.05 -4 1.13±0.04 0.97±0.10 -16a 
LMWCysGly 1.00±0.02 1.22±0.02 23a 1.07±0.10 0.95±0.08 -12c 1.04±0.04 0.96±0.05 -8b 0.91±0.05 1.03±0.03 12a 






Our data suggest that EFV short- and long-term effects have different underlying mechanisms, 
which are related to the time-course of the drug’s biotransformation and are also 
tissue-dependent. In particular, they show that the hippocampus responds differently to the 
electrophilic/oxidative stress generated upon long-term EFV exposure than the other tissues 
investigated in this study. The herein reported findings are consistent with our previous report 
that long-term neurotoxic effects are related with increased plasma levels of 8-OH-EFV (Grilo 
et al., 2016).  
The formation of 8-OH-EFV is related with individual CYP metabolic capacity and with 
EFV-promoted auto-induction. We found major differences among tissues in the Cyp2b 
expression after EFV exposure. According to the higher mRNA levels, ECOD activity, and 
8-OH-EFV plasma concentrations, the Cyp2b induction by EFV in the liver had a delayed onset 
and reached high levels after long-term exposure. Two non-mutually exclusive reasons may 
account for these results: i) a delay period is necessary to reach the steady-state plasma 
concentrations of EFV and of Cyp2b induction; and ii) the products of EFV metabolism may 
have the same pharmacological effect in Cyp2b expression as the parent drug. 
The time required for a drug to maximally induce an enzyme is highly related with the half-life 
of the inducer, and the degradation half-life of the enzyme, which may be estimated from the 
clearance of the substrate after removal of the inducer (deinduction). In the case of inducers of 
their own metabolism, it is more difficult to predict this time course. EFV has a long half-life 
of 40-55 hours in healthy individuals (Vrouenraets et al., 2007) and 19 hours in HIV-infected 
patients (Csajka et al., 2003). After discontinuation, EFV can persist in plasma for 36-100 hours 
(Taylor et al., 2004), which anticipates a late onset of EFV effects on Cyp2b expression and a 
long time to attain maximum enzyme induction. In man, it takes at least 4 months to reach 
steady-state EFV-CYP2B6 induction and this period is characterized by a progressive increase 
of 8-OH-EFV plasma concentrations (Ngaimisi et al., 2010). The extent of auto-induction is 
not dependent on baseline EFV concentration (Zhu et al., 2009). However, it is dependent on 
baseline EFV clearance and the intrinsic capacity of CYP2B6 (Zhu et al., 2009; Ngaimisi et 
al., 2010). In fact, the 8-OH-EFV/EFV ratio has been considered a metabolic phenotype for 
CYP2B6 activity (U.S. Food and Drug Administration, 2014). This could in turn implicate 
8-OH-EFV or a metabolite generated from it (Bae et al., 2011; Aouri et al., 2016) as a 
maintainer of the induction period. Moreover, these observations suggest that the baseline 
8-OH-EFV/EFV ratio may be relevant to predict the extension of the induction and deinduction 
periods. Our data support the hypothesis that there is a differential contribution of EFV and 
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8-OH-EFV to short- and long-term neurotoxic effects and that the Cyp2b induction period 
contributes to these differences.  
Based on this last assumption, it is expectable that low CYP2B6 metabolizers or patients taking 
CYP2B6 inhibitors will have higher plasma EFV concentrations and lower baseline clearance, 
as well as shorter and lower induction, resulting in EFV accumulation that may induce direct 
toxicity. These patients are at higher risk of experiencing earlier neurologic adverse reactions 
than high metabolizers. This is in line with the earlier EFV discontinuation reported for low 
CYP2B6 metabolizers (Wyen et al., 2011) and it is noteworthy that in vitro studies have 
associated EFV with mitochondrial dysfunction in hepatocytes, neurons and glia cells 
(Apostolova et al., 2015b). By contrast with slow metabolizers, ultra-rapid CYP2B6 
metabolizers present an increased plasma accumulation of 8-OH-EFV, along with a higher 
clearance of EFV.   
While tissue availability restricts the study of CYP2B6 regulation in man, there are several 
similarities that make the rat a suitable model for the study of drug metabolism. For instance, 
the CYP2B family is similar between humans (CYP2B6) and rodents (Cyp2b1 and Cyp2b2), 
with high homology and sharing of substrates (Miksys et al., 2000). This is also true for enzyme 
induction, as shown by studies involving phenobarbital (Ganem et al., 1999). Moreover, 
CYP2B6 expression is regulated by the constitutive androstane receptor (CAR) (Sueyoshi et 
al., 1999) and rat Cyp2b has also been reported to be regulated by the orthologous CAR 
(Muangmoonchai et al., 2001). Nonetheless, our animal model does not mimic low 
metabolizers as rats have high metabolic capacity (Mutlib et al., 2000). In fact, a high Cyp2b 
induction in liver was observed in the present study.  
EFV is able to modulate 8-OH-EFV clearance by two mechanisms: i) inhibition of 
8-OH-EFV-Glc formation (Ji et al., 2012; Grilo et al., 2016); and ii) CAR-dependent increase 
of phase II metabolism (Maglich et al., 2003). The latter is more conceivable to happen in the 
liver than in brain tissues, which have lower activity of phase II enzymes (Ouzzine et al., 2014).  
It is still to be demonstrated if 8-OH-EFV is able to cross the BBB. Nonetheless, the recently 
observed correlation between plasma 8-OH-EFV concentrations and mood changes in 
HIV-positive patients points in this direction (Grilo et al., 2016). The likelihood of low 
8-OH-EFV formation in the prefrontal cortex and hippocampus also suggests a contribution of 
the peripheral pool of the metabolite to the neurological effects of EFV. Moreover, the 
down-regulation of the Cyp2b expression and activity (ECOD) in hippocampus herein observed 
suggests a protective response of the tissue from exposure to in situ generated 8-OH-EFV by 
decreasing EFV conversion into 8-OH-EFV. It also suggests that 8-OH-EFV or its metabolites 
may behave as CAR inverse agonist in hippocampus.  It is interesting to note that Cyp2b1 was 
mainly induced in the liver, while Cyp2b2 induction was predominant in the prefrontal cortex, 




Cyp2b2 are known to be differentially regulated by several compounds. For instance, Cyp2b1 
is more inducible by phenobarbital than Cyp2b2 (Christou et al., 1987); on the other hand, 
4-n-alkyl-methylenedioxybenzene-type derivatives induce Cyp2b2 to a larger extent than 
Cyp2b1 (Marcus et al., 1990). We found the prefrontal cortex to exhibit higher expression of 
Cyp2b2, but this was not translated into higher Cyp2b activity, which may indicate that the 
contribution of this isoform to ECOD formation is minimal. The specificities of each 
compartment regarding the expression of enzymes and drug transporters (Miksys and Tyndale, 
2002), along with  EFV and 8-OH-EFV penetration and accumulation (Avery et al., 2013b) 
will ultimately determine the exact concentrations of 8-OH-EFV in loco.  
Once in the brain, the formation of electrophilic species upon oxidation of 8-OH-EFV is a 
plausible event for EFV toxicity (Harjivan et al., 2014), similarly to what happens with 
endogenous neurotoxins (Baumgarten and Lachenmayer, 2004). The brain is highly susceptible 
to oxidation, due to its high oxygen consumption rate and its poor antioxidant defenses, when 
compared to other tissues (Dringen et al., 2005; Ballatori et al., 2009). Additionally, the 
oxidation of 8-OH-EFV might be confined to a few compartments since it depends on the 
availability of oxidases (Meyer zu Schwabedissen et al., 2012). Thus, 8-OH-EFV oxidation is 
likely related to a change in the subtle balance among redox forms of thiols. In fact, the 
time-dependent thiol redox changes that we found do not seem to be linked to the initiation of 
the toxicity pathway or the formation of a toxic metabolite. They may rather be associated with 
a response to a toxic insult triggered by increased 8-OH-EFV concentrations. In the same way, 
the changes observed in the tissue-dependent thiolomic redox code suggest a tissue-specific 
response to the electrophilic/oxidative stress generated by 8-OH-EFV oxidation.  
There is increasing awareness of the ubiquitous role of oxidative stress in neurotoxicity (Sayre 
et al., 2008). The oxidation of thiol groups is one of the first events during oxidative 
stress-mediated damage (Grant et al., 1999), LMWGSH is the most abundant thiol/disulfide in 
cells, being present mainly in its reduced form (Rossi et al., 2009. Upon exposure to oxidative 
stress, a tissue response involving GSH increase is expected. This may happen in four different 
ways: increase of LMWGSH synthesis, decrease of LMWGSH degradation, regeneration of GSSR, 
or displacement from S-thiolated proteins.   
The RSH and RSSP profile of the liver was completely distinct from that of brain tissues. The 
increase in PSSCysGly and all RSH analytes observed in the liver may represent an adaptive 
response to 8-OH-EFV insult, which was not observed in prefrontal cortex or hippocampus. 
Recently, GSSP formation was proposed as a mechanism of resistance to paracetamol-induced 
hepatotoxicity (McGarry et al., 2015), by conferring protection against electrophilic stress in 
vivo. A reasonable explanation is that S-thiolation protects the protein thiol groups from acting 
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as nucleophiles, thereby preventing covalent protein modification by electrophilic metabolites. 
Moreover, S-thiolation has a key role in regulation of macromolecular interactions, directional 
trafficking proteasomal degradation, folding and activity of proteins (McGarry et al., 2015). 
This helps to explain why, despite mostly metabolized by the liver, EFV has rarely been 
associated with hepatotoxicity (Rivero et al., 2007). Additionally, it also highlights that the 
evaluation of genetic variability of crucial thiol redox enzymes (Hayes et al., 2005; Townsend 
et al., 2009; Lok et al., 2012) might be useful to identify patients at higher risk for EFV-induced 
toxicity.  
While intracellular proteins are predominantly S-glutathionylated, plasma is poor in LMWGSH 
content; as such, plasma proteins are mainly S-cysteinylated (Rossi et al. 2009). In plasma, 
GSSP and PSSCysGly vary inversely with CysSSP (Rossi et al. 2009). In the current study, the 
major variation observed in plasma was an increase in GSSP. This is consistent with increased 
S-glutathionylation at higher 8-OH-EFV concentrations, to replace the displacement of CysSH 
from CysSSP. The released CysSH can then be oxidized to CysSSCys. CysSSCys can penetrate 
the CNS, being the main source of CysSH, and consequently of GSH, in the brain (Wang and 
Cynader, 2000). Similarly, small dipeptides such as CysGly can also penetrate the CNS and 
contribute to the CysSH pool (Dringen et al., 1997; Dringen et al., 1998). Thus, our data point 
towards a higher efflux of cystine and CysGly from plasma into brain tissues, to increase the 
pool of intra-tissue reduced thiols. However, this peripheral contribution may not be sufficient, 
requiring intracellular displacement of CysSH and GSH from the CysSSP and GSSP brain pool. 
This was particularly evident for hippocampus compared to prefrontal cortex, suggesting that 
hippocampus is more vulnerable to oxidative/electrophilic stress at higher 8-OH-EFV 
concentrations. This might explain the down-regulation of Cyp2b in this tissue, in order to 
decrease 8-OH-EFV formation.  
It is noteworthy that the majority of RSSP in plasma are formed with albumin (Di Simplicio et 
al., 2005) and that EFV is highly bound to this protein (Wanke et al., 2013). However, it is not 
known to what extent these changes in plasma RSSP modify the fraction of EFV available to 
cross the BBB, or its intra-tissue accumulation. Moreover, the information available on 
8-OH-EFV affinity for plasma proteins is scarce. 
Interestingly, the EFV-exposed animals presented a significant slowing of body growth, 
similarly to what was described before (Aïssi et al., 2015). This might be related to an increase 
in the metabolism through hepatic CAR activation. It is known that CAR activation markedly 
improves fatty liver, by inhibition of hepatic lipogenesis and induction of β-oxidation (Dong et 
al., 2009). Also, in an in vitro study performed by El Hadri and collaborators, EFV prevented 




adipocyte differentiation (El Hadri et al., 2004). In accordance with these reports, EFV use is 
















CHAPTER 3                                            
Long-term exposure to efavirenz impairs 
































EFV is an anti-HIV drug which is chronically used and prescribed to both adults and children. 
Long-term exposure to EFV has been associated with higher concentration of its main 
metabolite 8-OH-EFV and to increased electrophilic/oxidative stress in brain. Nonetheless, 
whether this translates into neurological impairments is still unknown. The aim of the present 
work was to evaluate the neurological phenotype and brain molecular changes in rats long-term 
exposed to EFV.  
Male Wistar rats were orally exposed to EFV during 36 days and their memory and emotional 
performance were evaluated. Brain tissues were histologically evaluated and markers of brain 
function were assessed by immunofluorescence. The EFV group displayed a slower learning 
curve during the acquisition phase of the MWM test (p=0.004) and a normal behavior during 
the probe test, suggesting an impairment in memory acquisition without memory retrieval 
disturbance. The short-spatial memory was also compromised in the EFV -treated group, as 
assessed by the Y Maze test (p=0.02). Additionally, the EFV group spent more time in the open 
arms in the Elevated Plus Maze test (p = 0.003), thus revealing lower anxiety levels. Finally, 
no differences were identified between groups either in depressive-like or locomotion behavior, 
as assessed by Forced Swim and Open Field tests, respectively. Histopathological analysis of 
the brains showed any evidence of neuronal cell death. However, a decrease in neuronal 
dendrites and in markers of neuronal function, were found in the hippocampus of EFV group. 
These data suggest that EFV impairs hippocampus-dependent learning memory, mimicking 
EFV chronic neurotoxic effects in man. This is seemingly a suitable model for the assessment 










3.2 MATERIALS AND METHODS  
	
	
3.2.1 Drugs and Chemicals  
 
EFV was kindly provided by Dr. Frederick A. Beland (National Center for Toxicological 
Research, Arkansas, USA). The primary antibodies used were the following: 
microtubule-associated protein 2 (MAP2) and synaptosomal-associated protein 25 (SNAP-25) 
from Sigma-Aldrich (M4403 and S9684, respectively); FosB from Santa Cruz Biotechnologies 
(SC-515210) and glial fibrillary acidic protein (GFAP) from Millipore (MAB3402). The 
secondary antibodies were Alexa Fluor® 488 goat anti-rabbit (A-11034) and Alexa Fluor® 594 
goat anti-mouse (A-11005) and were from Invitrogen. The VECTASHIELD media with 





Sixteen male Wistar rats (6 weeks old, with mean body weight 230 ± 21 g) were obtained from 
the NOVA Medical School animal facility and were housed two per cage in polycarbonate cages 
with wire lids (Tecniplast, Italy), and maintained under controlled environmental conditions 
(12-h light/dark schedule [8 am-8 pm] at 22 ± 2.0 °C, 60 ± 10% humidity, with food (SDS 
RM1, Special Diets Services, UK)) and reverse osmosis water supplied ad libitum. Animals 
were Specific Pathogen Free (SPF) according to FELASA recommendations (Nicklas et al., 
2010).  
Applicable institutional and governmental regulations concerning ethical use of animals were 
followed, according to the NIH Principles of Laboratory Animal Care (NIH Publication 85-23, 
revised 1985), the European guidelines for the protection of animals used for scientific purposes 
(European Union Directive 2010/63/EU) and the Portuguese Law nº 113/2013. Experimental 
procedures were previously approved by the Institutional Ethics Committee of the NOVA 









3.2.3 Experimental Protocol 
 
Rats were randomly assigned into two groups of 8 animals each: EFV group (administered with 
EFV 9 mg/Kg/day suspended in reverse osmosis water – 1.5 mL) and CTL group (administered 
only with vehicle – 1.5 mL).  
EFV or vehicle gavage administration was performed using a sterile polypropylene feeding 
tube (15 gauge; tip diameter: 3 mm; length: 78 mm; Instech Laboratories, Inc., USA) to reduce 
the risk of trauma, perforation and cross contamination and lasted 36 days. All animals 
underwent a 7 days’ period of handling acclimatization. Rats were handled daily for a period 
of 2 minutes each, by the same individual and accustomed to the gavage position, in a different 
animal facility procedures room. 
Animals were weighted at baseline and twice a week throughout the entire study. The amount 
of EFV was adjusted accordingly in order to ensure a daily dose of 9 mg/Kg. EFV was weighed 
immediately before administration, suspended in the vehicle and labeled individually for each 
rat on a daily basis. EFV or vehicle was administered daily to the animals at approximately the 
same schedule (9:00 to 9:30 am).  
After 36 days of EFV administration, five consolidated behavioral tests were performed during 
one week. EFV administration was continued throughout this period.  
At the end of the behavioral tests, approximately 2 hours after EFV delivery, rats were 
anesthetized by intraperitoneal injection with medetomidine (0.5mg/kg body weight; 
Domitor®, Pfizer Animal Health) and ketamine (75mg/kg body weight; Imalgene 1000®, 
Merial). Four animals from each group were perfused transcardially with phosphate buffered 
saline followed by 10% neutral buffered formalin (NBF), under deep anaesthesia, for 
histological and immunohistochemical analysis. Thereafter, the head of the animal was 
immersed and fixed for 24 hours in 10% NBF before brain removal. 
  
 
3.2.4 Behavioural tests  
 
The animals were routinely tested during the first half of the light phase of their light/dark cycle, 







3.2.4.1 Elevated Plus Maze (EPM) test 
 
EPM test is one of the most commonly used in animal models for the evaluation of anxiety 
(Pellow et al., 1985). This test consists in two ‘open’ (no walls; 5 x 29 cm) and two ‘closed’ 
arms with 29 cm high walls, arranged perpendicularly, and elevated 50 cm above the floor 
(Pellow et al., 1985).  
Each animal was placed at the center of the apparatus, facing one of the open arms. Each test 
lasted 5 minutes and all testing sessions were performed between 10:00 am and 12:00 pm in a 
sound-attenuated room. The maze was cleaned with a 70% ethanol solution and rinsed with 
water after each test to avoid odor cues. The total time spent in the open arms and the total arms 
entries (number of entries in open and closed arms) were used as anxiety and locomotor 
measures (Pellow S., 1985).  All experiments were conducted by the same individual blinded 
to experimental groups. 
 
 
3.2.4.2 Open Field (OF) test 
 
The OF test allows a simple and rapid measurement of animal locomotor activity and anxiety 
(Seibenhener and Wooten, 2015). A square arena (66 × 66 x 66 cm) that was surrounded by 
vertical walls was used herein. Three different zones were defined for analysis (Choleris et al., 
2001): (1) the area adjacent to the wall (1896 cm2; “arena periphery”); (2) the central area of 
the arena (552 cm2; “arena center”); (3) the intermediary area between the two previous ones 
(1908 cm2). The percentage of time spent in each zone, the total distance travelled (cm) and the 
average speed (cm/s) were recorded. Rearings (episodes of animals standing on their hind legs) 
and the number of fecal boluses were also manually monitored. The animal was placed at the 
arena center and was allowed to explore the maze for 5 minutes. At the end of the 5 minutes 
test, the rat was placed into its home cage, and the maze was cleaned with a 70% ethanol 
solution and rinsed with water after every test, to prevent avoid odor cues. All experiments 
were conducted by the same individual blinded to experimental groups. Rat’s movements were 
recorded and analysed using the video-tracking software – SMART® 2.5 (PanLab, Barcelona, 
Spain). The reference point used by the software to determine the position of the animal was 








3.2.4.2 Y–Maze (YM) test 
 
YM test is aimed to evaluate the short-term spatial memory of the rodent, and is based on its 
disposition to explore new environments (Conrad et al., 1996). The apparatus consisted in a Y 
shape maze, as described by (Salamone et al., 1994). The animal was placed at the end of the 
‘start’ arm and allowed to explore the ‘start’ arm and the ‘other’ arm for 10 minutes (beginning 
from the time that the rat first left the start arm). An opaque door blocked the access to the third 
arm of the maze (‘novel’ arm). The rat was then removed from the maze and returned to its 
home cage for 1 hour. In the test phase the rat was placed again in the ‘start’ arm of the maze, 
the door of the ‘novel’ arm was removed and the rat was allowed to explore the maze for 5 
minutes (from the time that the rat first left the start arm). The number of entries and amount 
of time (s) the animal spent in each arm of the Y-maze was recorded to assess short-term 
memory.  
Between each rat, the maze was cleaned with a 70% ethanol solution and rinsed with water to 
avoid odor cues. All experiments were conducted by the same individual blinded to 
experimental groups. Rat movements were recorded and analysed using the video-tracking 
software – SMART® 2.5 (PanLab, Barcelona, Spain). The reference point used by the software 
to determine the position of the animal was the centre of the rat’s dorsum. 
 
	
3.2.4.3 Morris Water Maze test 
 
To evaluate the existence of long-term spatial memory deficits in EFV vs. control animals, the 
animals were submitted to spatial reference memory test described by Morris and co-authors 
(1982).  The maze consisted of a large circular tank (1.8 m in diameter, 0.6 m in height) of 
water (23 ± 1 oC) that was made opaque with the addition of non-toxic water-based black paint. 
An escape platform (10 cm in diameter) was submerged 1 cm below the water. Visual cues 
were placed on the walls of the testing room, to be used as spatial references by the rats. An 
automated tracking system (Smart 2.5, PanLab, Barcelona, Spain) monitored the following 
parameters: escape latency (s); swim path length (cm); average speed (cm/s); and time spent in 
each quadrant (%).  
Rats were given spatial (acquisition) training consisting of four trials per day for 4 days, in 
which the platform was placed at a fixed position in the center of one of the four quadrants of 
the tank (platform Q, left, right and across). The starting position, at which subjects were placed 
in the tank facing the wall, was randomly chosen across trials. Inter-trial interval period was 15 
minutes, during which animals were towel-dried and placed in a heated incubator (25 oC) to 
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prevent hypothermia. The maximum trial duration was 60 s, after which animals were manually 
guided to the platform if they failed to locate it. Once animals reached the platform, they were 
allowed to remain there for 20 s. On the 5th day, animals were subjected to a probe test in which 
the platform was removed and animals were allowed to swim freely for 60 seconds, while 
recording the percentage of time spent on each quadrant. All experiments were carried out by 
the same individual blinded to experimental groups. Rat movements were recorded and 
analysed using the video-tracking software – SMART® 2.5 (PanLab, Barcelona, Spain). The 
reference point used by the software to determine the position of the animal was the center of 
the rat’s dorsum. 
 
 
3.2.4.5 Forced Swim (FS) test 
 
The FS test is used to infer depressive-like behavior in rats, by evaluating their latency to 
immobility (or to despair; LTD) and the time spent swimming versus the time spent floating 
(percentage of time spent immobile) (Porsolt et al., 1978a). The test involves two exposures to 
a vertical Plexiglas cylinder (height: 45 cm, diameter: 19 cm) filled with water (23 oC) at a 
depth that makes it impossible to reach the bottom with hind paws (28 – 30 cm).  
On the first day of the two test days, all animals were gently placed individually in the cylinder 
during 10 minutes. Before animals return to their home cages, they were dried and exposed to 
infrared light, in order to prevent hypothermia. On the second day, the animals were placed in 
the same cylinders for 5 minutes. The water was changed after each session. The rat was judged 
to be immobile when it floated passively, making only small movements to keep its nose above 




3.2.5 Histological and Immunofluorescence assays 
 
 For histological analysis, animals were deeply anesthetized for transcardial perfusion with 
PBS, followed with 10% NBF; and after perfusion, the head was further immersed into neutral 
buffered formalin for 72h. Brain was then removed from the skull, trimmed (10-level trimming, 
according to (Bolon et al., 2013), and routinely processed for paraffin embedding and 
sectioning. Hematoxylin and eosin-stained and cresyl violet-stained 4 µm sections were 
screened by a pathologist blinded to experimental groups, in a Leica DM2500 microscope 




The following procedure was applied for immunofluorescence analysis of the frontal cortex 
and hippocampus: 4 µm sections, which were previously subjected to heat-induced epitope-
retrieval (HIER) using DAKO PT Link (Dako, Glostrup, Denmark) and to quenching of 
endogenous peroxidase activity with 3% hydrogen peroxide, were blocked with goat serum 
diluted in glycine 0.3M (1:50), for 30 minutes at room temperature.  There was an ensuing 
incubation with the following primary antibodies [diluted in 0.1% (w/v) BSA in PBS 1X] for 
6o minutes at room temperature:   anti-MAP2 (1:1500), anti-GFAP (1:1500), anti-FosB (1:200) 
and anti-SNAP-25 (1:1500). Slides were then rinsed with PBS 1X and incubated with 
secondary antibody [diluted in 0.1% (w/v) BSA in PBS 1X, 1:1000] for 120 minutes, at room 
temperature Sections were mounted in VECTASHIELD media with DAPI and examined by 
standard fluorescence microscopy using a Nikon Instruments Eclipse Ti-S Inverted Microscope 
(Hamamatsu digital camera C10600 ORCA-R2). Images were acquired with NIS-Elements AR-
3.2 and analyzed with ImageJ software. Images were taken on the same areas of the prefrontal 
cortex or hippocampus from each brain section, using identical microscopy parameters, 
including exposure time. 
 
 
3.2.6 Statistical Analysis 
 
Two-way ANOVA with Bonferroni post-test was used to compare CTL and EFV groups in the 
MWM acquisition curve. The Unpaired Student t test was used for EPM, OP, YM and FS tests. 
Data are expressed as mean ± SEM. One-way ANOVA was used for immunofluorescence. 
Data are presented as EFV/CTL ratio. Statistical analysis was performed using GraphPad Prism 
(GraphPad Software Inc., version 5.01, San Diego, CA). Statistical significance for all tests was 





3.3.1 Animal data 
 
While daily food intake was similar for both animal groups (26 ± 1 g for both), the EFV-
exposed rats (34 ± 1 mL) consumed significantly less (p=0.022) water	per	day than the CTL 
group (39 ± 1 mL). EFV-exposed rats showed a lower (p=0.049) body weight gain (130 ± 8 g) 
than control animals (157 ± 9 g). 
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3.3.2 Behavioural tests 
  
On the MWM, EFV-exposed animals showed an impaired learning ability to swim to the scape 
platform when compared to CTL animals (Figure 10A). The onset of this impairment in the 
EFV group was on day 2 (p=0.004). On the other hand, the retention ability of EFV animals 
was not compromised, once in the probe test there was no difference in the time spent in the 
platform quadrant between EFV and the CTL groups (Figure 10B). The average speed (cm/s) 
and total swimming distance (cm) on probe test were similar between groups (data not shown). 
 
The YM test revealed short-term spatial memory deficits in EFV-treated rats as indicated by a 
significant reduction of the percentage of time and entries in the ‘novel arm in comparison to 
CTL group (Fig. 10C: 24 ± 2 versus 18 ± 1%; p=0.038; Fig. 10D: 46 ± 1 versus 51 ± 3%; 
p<0.001). No differences were found to the total number of entries between EFV and CTL rats 
(Fig. 10E). The reduced novelty-seeking of EFV-treated rats indicates that these animals had 
significant short-term spatial memory impairment.   
    
In the EPM test, EFV group presented a lower anxious-related behavior since these rats had 
more percentage of entries in the open arms and spent more time (%) in these arms than the 
control group (Figure 10F: 53 ± 1% versus 49 ± 1%; p=0.02; Figure 10G: 26 ± 1.4% versus 19 
± 1.3%; p=0.003). Additionally, EFV did not alter the locomotor performance, since there was 









Figure 10. Behavior evaluation of long-term efavirenz-exposed Wistar rats. (A) Morris Water Maze (MWM) protocol (n=7 for each group): Learning curve of escape 
latencies over 4 days of acquisition. Two-way ANOVA, **p=0.004. (B) Probe Test: Time spent in each quadrant in hidden platform test. ns, ANOVA. Y Maze (YM) protocol 
(n=6 for each group): (C) Time (%) spent in the start, other and novel arm of the maze.  (D) entries (%) in the other and novel arms; (E) total number of entries. Unpaired 
student´s t- test, *p=0.04, ***p<0.001. Elevated Plus Maze protocol (n=7 for each group): (F) Time (%) spent in open arms; entries (%) into the open arms over 5 minutes. 
Unpaired student´s t- test, ** p= 0.003, * p= 0.015.   Data from all tests are expressed as the mean ± SEM. 	
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Likewise, it was also performed the OF arena test to further analyze rodent anxiety-like 
behavior and their locomotor activity. No differences between the time spent in periphery or in 
the center were found (Fig.11), further confirming that EFV-treated rats do not show an anxiety-
like behavior. Also, the EFV treatment did not induce changes in the locomotor activity of the 
animals. This is in line with the data obtained from MWM test.  
 
Finally, latency-to-despair (LTD) was evaluated by FS test. No differences were found between 
CTL and EFV-treated groups regarding depression evaluation (Fig.12).  
 
	
Figure 11. Open Field test. Time spent in the arena center and in arena periphery by control (n=8) and 
EFV-exposed animals (n=8), Unpaired student´s t- test.  Data are expressed as the mean ± SEM. 
 
	
Figure 12. Forced swim test. The latency to despair (time before immobility) over 5 minutes for control 







3.3.3 Histological and immunofluorescence analysis 
	
An in-depth histopathological analysis of the brains from EFV animals is provided herein. In 
particular, the frontal, parietal, temporal and occipital lobes of the cerebral cortex and cingulate 
gyrus, the caudate putamen, amygdala and thalamus, piriform cortex, cerebellar Purkinje cell 
layer and hippocampus showed no changes, including no evidence for neuronal cell death (Fig. 
13). White matter tracts in the cortex were also unaltered.  
Concerning the immunofluorescence analysis, major differences were found in hippocampus 
and prefrontal cortex, between CTL and EFV-treated rats. Rats exposed to EFV had a 
significant decrease in Map2 expression in the gyrus dentate and in CA1 region of the 
hippocampus, in comparison with the prefrontal cortex (p<0.001) (Fig. 14A and B); and the 
same pattern was found for FosB, as this protein was markedly decrease in the gyrus dentate of 
EFV group, followed by CA1 region, resulting in a bigger difference for prefrontal cortex 
(p<0.001) (Fig. 14A and C). No differences were found for GFAP expression (Fig. 16). For 
SNAP-25, differences were only found in the gyrus dentate of the hippocampus, which showed 
a slight decrease in expression when compared with the CA1 region (p<0.05) and prefrontal 
cortex (p<0.05) (Fig. 15). However, when comparing SNAP-25 between control and EFV 
















































Figure 13. Representative microphotographs of prefrontal cortex (A), frontal cortex (B and C), 
hippocampus (D) and cerebellum (E) from control and efavirenz-exposed rats. No changes or 
















Figure 14. (A) Representative immunofluorescence analysis of hippocampus stained for Map2 (red) and FosB (green). (B) Quantification of Map2 and (C) FosB 





Figure 15. (A) Representative immunofluorescence analysis of hippocampus stained for SNAP-25. (B) Quantification of SNAP-25 immunofluorescence intensity in 








Figure 16. (A) Representative immunofluorescence analysis of hippocampus stained for GFAP. (B) Quantification of GFAP immunofluorescence intensity in 






As most CNS adverse reactions of EFV occur in the first weeks of treatment, the knowledge 
about the mechanisms underlying them, even if it is very limited, is related to short-term EFV 
exposure. We have previously reported that long-term EFV exposure of Wistar rats lead to 
significant changes in biotransformation of EFV via Cyp2b in liver, prefrontal cortex and 
hippocampus, that differs from short-term exposition. These changes were accompanied by an 
accumulation of 8-OH-EFV in plasma and with major tissue differences in 
electrophilic/oxidative stress induced upon EFV exposure as evaluated by thiol redox code, 
with marked decrease of glutathionylation of proteins in hippocampus, a decrease of lower 
magnitude in pre-frontal cortex and no variation in the liver. Herein, we have evaluated the 
molecular alterations in neurons, astrocytes and synaptic function of prefrontal cortex and 
hippocampus induced by long-term exposure to EFV and their relation to a behavior profile of 
anxiety, depression and cognitive impairment. 
 
Our results show for the first time that long-term EFV exposure in rats triggers short- and long-
term spatial memory deficits observed in YM and MWM tasks, respectively, that go along with 
a decrease in neuronal activity.  In both tests, the animals need to make associations among the 
spatial environment clues to perform a cognitive map that helps them to find out the platform 
localization (Morris et al., 1982) or to recognize the unvisited arm (Dellu et al., 1997). EFV 
exposure led to a slower learning curve during the acquisition of MWM, without affecting 
memory retrieval. Also, the reduced novelty-seeking of EFV-treated rats found in the YM 
indicates that these animals had significant spatial memory impairment. Usually, animals prefer 
to investigate a new arm (novel arm) of the maze than returning to one that was previously 
visited. These results mean that EFV-exposed rats have memory impairment, particularly 
linked to the hippocampus (Morris, 1984). Notably, this test non-aversive as it does not require 
food deprivation as the radial maze or electric foot-shook as inhibitory avoidance test. 
Therefore, this test is less prone to modify the motivational and emotional status of the animals 
(Bekker et al., 2006), avoiding confounding factors in the spatial memory parameters 
evaluated. 
There are only three studies with behavior evaluation upon EFV exposure (O'Mahony et al., 
2005; Romao et al., 2011; Gatch et al., 2013). These studies differ strongly in study aims, in 
EFV exposure time (1-36 days) and EFV administration route (intravenous or oral gavage). 
Our study is the first associating EFV with learning memory impairment by using MWN and 
YM, suggesting that our model is the one that best fits for studies on this purpose. Moreover, 
the Wistar rat is a suitable model for the study of EFV biotransformation into 8-OH-EFV as an 




and rat (Cyp2b1 and Cyp2b2) and as they share inducible mechanisms (Ganem et al., 1999; 
Sueyoshi et al., 1999; Miksys et al., 2000; Muangmoonchai et al., 2001).   
 
In our model, EFV did not induce anxiety. The animals spent more time in the open arms, 
presenting lower anxious-related behavior. In accordance with the results from the EPM, the 
locomotion from both groups was not affected in the Open Filed test, neither was it found an 
anxiety-like behavior. Our data differs from what was observed in mice exposed to the same 
EFV dose, which presented an elevated anxious behavior (Romao et al., 2011). In that study, 
similar results were found for another anti-HIV drug, the nevirapine (NVP). NVP and EFV 
share more than the mechanism of action. Both are inducers of their metabolism via CYP2B6 
through CAR activation (Faucette et al., 2007). Also, their toxicity is associated with reactive 
metabolites generated by bioactivation of phase I metabolites (Caixas et al., 2012; Harjivan et 
al., 2014). In man, NVP is not associated to neurotoxicity but to hepatotoxicity (Sanne et al., 
2005). Plausible contributors to explain this difference are, the selective accumulation of the 
phase I metabolites in tissues, the capacity of each tissue to respond to electrophilic/oxidative 
stress as well as the availability of the enzymes that generate electrophile metabolites, the 
sulfotransferase in the case of NVP (Antunes et al., 2013) and the oxidases in the case of EFV 
(Harjivan et al., 2014). Despite sulfotransferases are present in brain, their activity is 300-fold 
lower than in liver (Rajkowski et al., 1997), which might mean that brain is not so capable of 
producing NVP toxic metabolite (12-sulfoxy-nevirapine). Thus, the effect found by Romão and 
collaborators (2011) might be related to the capability of NVP to be a CAR ligand, rather than 
the formation of toxic metabolites. Interestingly, EFV was shown to be genotoxic at the brain, 
but not at the liver (de Oliveira et al., 2014). Our previous data showed lower Cy2b mRNA 
levels in hippocampus are lower upon long-term EFV exposure, differently to what happens at 
the liver or prefrontal cortex. It is difficult to compare our results as these authors used mice 
and there are species-related differences on Cyp2b induction (Pustylnyak et al., 2007). and 
behavior tests can induce different fear/stress in the species, resulting in a potentially different 
neurotransmitter and brain area stimulation (Porsolt et al., 1978b).  
 
We have not explored if this low-anxiety behavior was related to an absence of fear or to a 
hallucinogenic effect. Patients on EFV complain of hallucinations, vivid dreaming and 
psychosis (Gutierrez et al., 2005; Cespedes and Aberg, 2006). There are reports on the use of 
EFV by non-infected teens who crush the pills and smoke the powder for its psychoactive 
effects (Marwaha, 2008; Sciutto, 2009). EFV has been describe as having an LSD-like effect, 
in the manner that it can be a partial agonist of the 5-HT2A receptor an it can block dopamine 
and serotonine uptake (Gatch et al., 2013), similar to other recreational drugs like cocaine, 
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methamphetamine and MDMA (Han and Gu, 2006). EFV might also have effects on serotonin 
as they compete for CYP2B6 metabolism (Fradette et al., 2004) and EFV is an inducer of this 
CYP450 isoform.  
 
Data obtained in the Forced swim test suggested no depression upon EFV exposure. Depression 
has been reported in a few clinical studies with EFV-treated patients, but the relation between 
EFV use and higher risk of depression is not easy defensible (O'Mahony et al., 2005; Journot, 
2006). 
 
EFV and 8-OH-EFV were shown to induce cell death in primary hippocampus cell cultures 
(Tovar-y-Romo et al., 2012). To evaluate the effect of EFV in our model, histopathological 
analysis of the brain was performed and no significant changes or signs of neuronal cell death 
were seen in any of experimental groups or areas of the brain analysed. Also, considering that 
MWM test has been introduced as an instrument with particular sensitivity to the effects of 
hippocampal lesions in rats (Morris et al., 1982), we have explored if any alterations regarding 
neuronal dendrites (Map2) (Lewis et al., 1989) and neuronal activity (FosB) (Flavell and 
Greenberg, 2008) were present in our animal model. Levels of Map2 and FosB were 
significantly decreased in hippocampus, both gyrus dentate and CA1 region, and no alterations 
were found in prefrontal cortex. At the dentate gyrus, neurogenesis has an important role in 
hippocampus-dependent learning and memory (Eriksson et al., 1998; Shors et al., 2002; Snyder 
et al., 2005). Accordantly with our data, a decrease in the proliferation of neural stem cells 
induced by EFV was observed in vitro and in the subventricular zone of C57BL/6 mice (Jin et 
al., 2016). The decrease found in Map2 indicates a loss of dendritic spines (Bernhardt and 
Matus, 1984). This suggests that this effect is mediated by the accumulation of 8-OH-EFV 
associated with long-term EFV exposure. This corroborates with the previous in vitro studies 
of Tovar-y-Romo showing that the metabolite 8-OH-EFV is one order of magnitude more 
potent in inducing dendritic spines injury than EFV itself (Tovar-y-Romo et al., 2012). In 
rodent models of aging and AD, decreased Map2 levels has been shown to be coincident with 
an increase of Aβ peptides in CA1 dendrites (Takahashi et al., 2013), early dendritic 
degeneration and reduction in total dendritic area (Moolman et al., 2004). Also, an in vitro 
study has revealed an association between EFV exposure and an increased production of Aß 
plaques due to increased oxidative stress conditions (Brown et al., 2014). Soluble Aβ oligomers 
represent the most toxic form of Aβ peptide, which are mediators of inflammation (Bradt et al., 
1998; Murakami et al., 2005) and oxidative stress (Murakami et al., 2005), and are critical in 
inducing cognitive impairment and synaptic dysfunction (Lue et al., 1999). Corroborating the 




neuronal activity. FosB has been associated with impairment in spatial memory (Solecki et al., 
2008).  
 
SNAP-25 was analysed as a surrogate of synaptic activity. Our data showed a slight decrease 
at the dentate gyrus. This protein is a component of SNARE complexes that mediate the release 
of neurotransmitters (Sollner et al., 1993; Tafoya et al., 2006) and has been associated to 
cognitive deficit (Braida et al., 2015).  
 
Recent evidence support that 8-OH-EFV can be bioactivated (Harjivan et al., 2014). Several 
authors have been shown that electrophiles and free radicals generation could negatively impact 
the function of proteins and thereby interfere with axonal transport or pre-synaptic 
neurotransmitter release (Asanuma et al., 2003; Lopachin and Decaprio, 2005). This has been 
described for several toxins as acrolein or acrylamide (Lopachin and Decaprio, 2005), to 
L-DOPA and dopamine (Asanuma et al., 2003). The 8-OH-EFV has also been shown to induce 
an alteration in the astrocytes glucose metabolism (Brandmann et al., 2013), which lead us to 
evaluate astrocytes population in hippocampus and prefrontal cortex. As no changes in GFAP 
expression were seen, we can speculate that astrocytes may be more protected or not so 
vulnerable to EFV-toxicity, compared to neurons.   
 
A slower weight gain was observed for EFV-exposed animals when compared with CTL rats, 
which is in accordance to ours and others (Aïssi et al., 2015) previous observations. This was 
not associated with reduced food consumption, since no differences were found between the 
two groups. A possible explanation could be related with a decrease in growth hormone 
production within the hippocampus, where this hormone responds to several factors including 
exposure to environmental stimuli (Vander Weele et al., 2013). A slower weight gain was also 
demonstrated in other exposure conditions associated with hippocampus injury and oxidative 
stress as chronic intermittent hypoxia (Diogo et al., 2015) or methotrexate (Seigers et al., 2008).  
 
The data herein presented suggest that EFV significantly impairs neurological performance in 
animals, mimicking long-term neurotoxic effects observed in HIV-patients. This effect was 
particularly evident for hippocampus-dependent learning and memory. In clinical setting, 
approximately 40 - 50% of patients receiving EFV suffered from cognitive disorders, whereas 
23 - 29% are related to memory (Lochet et al., 2003; Ma et al., 2016). Evidently some important 
aspects of human pathology will probably never be accessible in animal models, but these 
treatment conditions in Wistar rats represent a suitable model that replicates human 
phenotypical (behavioural) features. We believe that this will permit to get further insights into 
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the molecular mechanism of EFV-induced neurotoxicity and explore the effect of electrophile 




Figure 17. Schematic representation of the toxic outcomes induced by long-term efavirenz 

































The starting premise for this research work was the contradictory data in literature regarding 
the dependency of CNS adverse reactions on EFV concentrations (Ngaimisi et al., 2010; Cho 
et al., 2011; Habtewold et al., 2011; Aouri et al., 2016).  
Data (unpublished) from our lab TDM unit (Fig. 18) and from others (Kwara et al., 2010), show 
that among patients on the recommended dose of EFV, 600 mg/day, there are a great percentage 
of patients that manifest CNS adverse reactions within therapeutic concentrations (1 – 4 mg/L, 
Marzolini et al., 2001). Additionally, there are patients on 800 mg daily dose that had lower 

















Figure 18. Data from the Therapeutic Drug Monitoring Unit of CEDOC-NMS (Unpublished data). 
Concentrations of efavirenz (Cthough) were measured in 43 patients on 600 mg of EFV and central nervous 
system adverse reactions were reported by the clinician. Therapeutic (1-4 mg/L) and toxic concentrations 
(above 4 mg/L) were defined according to Marzolini and co-authors (2001). *p=0.015, Chi-square. 
 
 
Data reflects the high inter-individual variability of EFV concentrations (Marzolini et al., 2001; 
Pereira et al., 2008), which is mainly attributed to its biotransformation.  Additionally, as many 
neuro-adverse reactions have a delayed onset, we hypothesized the role of EFV metabolite(s) 
accumulation in the genesis of neurotoxic effects. Therefore, the work herein presented was 
aimed at unraveling the role of EFV biotransformation in EFV-induced CNS adverse reactions 
in order to find mechanistically-oriented tools for its monitoring and for evaluating strategies 
with the ultimate goal of optimizing EFV use.   
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The top five studies that strongly supported our findings and influenced our choices in the 
progression of this thesis are herein enounced.  
One published in 2012 by Tovar-y-Romo and collaborators in Sprague-Dawley hippocampal 
neuronal culture, showing that 8-OH-EFV was a more potent neurotoxin than EFV itself 
(Tovar-y-Romo et al., 2012). The minimal toxic concentration used was three times lower than 
what is found in the CSF of HIV-infected patients (Tovar-y-Romo et al., 2012). This study 
placed 8-OH-EFV in the roadmap of EFV neurotoxicity mechanisms. However, this is an in 
vitro study and there was a need for the translation of this finding.  
  
The second, from 2011 by Khokhar and collaborators, showed that by inhibiting Cyp2b 
specifically in brain, the pharmacological effect of the anesthetic propofol is changed (Khokhar 
and Tyndale, 2011). The authors observed an increase in the sleep time that was related with 
propofol concentration in brain, but not with the concentration in plasma. Additionally, seven 
days of nicotine treatment can induce the expression of brain Cyp2b but not hepatic isoform, 
and this induction reduced propofol sleep time by 2.5-fold. This work elegantly showed the 
importance of studying CYP activity and regulation in brain and the need to find peripheral 
markers that reflect this brain activity.  
 
The third was published by Harjivan and colleagues in 2014, and showed that upon in vitro 
oxidation of 8-OH-EFV, this metabolite was prone to yield a toxic quinoid derivative (Harjivan 
et al., 2014), paving the way for a new and unexplored mechanism of EFV neurotoxicity. This 
was later corroborated by Oliveira et al (2014) that found a selective genotoxicity in brain but 
not in liver of mice exposed to EFV (de Oliveira et al., 2014).  
 
Finally, Ngaimisi and collaborators showed in 2010 that the metabolites profile changed over 
at least 16 weeks since EFV beginning and it is characterized by a decrease in EFV and increase 
in 8-OH-EFV concentrations (Ngaimisi et al., 2010). This long-term auto-induction effect is 
dose-, duration of treatment- and genetically-dependent. These data lead us to hypothesize that 
8-OH-EFV contributes differently to long- and short-term toxicity mechanisms. 
 
Herein are presented our final considerations, divided into four components. The first one 
summarizes the relevant findings of both clinical and animal studies. Then, it is described the 
added value of this work to the field. The next sections outline the main limitations of our work 




therefore unavoidable that there is some content overlap between these sections and the 
discussion section of each chapter. 
 
 
1. Summary of relevant findings 
  
In our opinion, to justify the discrepant data reported in literature about the correlation between 
EFV concentration and the occurrence of neuro-adverse drug reactions, we should not only 
considerer the inter-individual PK variability of EFV, but also the broad type of symptoms and 
the time for their onset. It is highly plausible that the panoply of described EFV-adverse 
reactions have different underlying mechanisms. For this reason, in the clinical study of the 
present work, we focused on mood changes. We choose to start with this adverse effect because 
it was the most observed in patients on long-term EFV exposure in our cohort. In short-term 
EFV use, sleep disorders are the major complaint. Our study showed that patients on long-term 
EFV exposure with mood changes complaints have higher plasmatic concentrations of 
8-OH-EFV than those without CNS complaints. To minimize confounding factors, we have 
limited the study to male patients with normal hepatic function and controlled viremia. One 
additional factor for this choice was the fact that the number of woman included on EFV is 
much lower than man, as EFV was classified as Pregnancy Category D by FDA clinicians avoid 
its prescription in woman in childbearing age. Differently to previous studies, we took in 
consideration the type of CNS adverse reaction, the time on EFV, the PK parameter and the 
concentration of non-conjugated 8-OH-EFV and 8-OH-EFV-Glc, which we consider a plus in 
our study design.  
 
In conclusion, with the results obtained in the first part of the present study, is possible to 
suggest the plasmatic concentration of 8-OH-EFV as a suitable parameter for TDM, particularly 
aimed at controlling mood changes.  
 
In the animal studies, we evaluated the time-course of EFV biotransformation and profiled 
Cyp2b induction by EFV in brain and liver as well as tissue thiolomic signatures. We observed 
that changes in these endpoints were particularly evident in brain at 36 days of EFV exposure 
and we ascertained that these molecular changes are related to an animal neurologic phenotype 
(memory impairment), similar to what is observed in patients.  
Long-term EFV exposure was associated to induction of Cyp2b at the liver, higher 8-OH-EFV 
plasma concentrations, memory and learning impairment, neuronal dysfunction in 
hippocampus, a brain area with unquestionable roles in cognition and emotional experiences 
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(Sigurdsson and Duvarci, 2016). Similarly to man, the Cyp2b induction by EFV had a delayed 
onset and persisted after long-term exposure, occurring a progressive increase in 8-OH-EFV 
formation. This effect is opposed in the hippocampus, showing a different regulation of Cyp2b 
in brain and liver upon long-term EFV exposure. According to our data interpretation, 
8-OH-EFV should be barely formed in the hippocampus, suggesting a contribution of a 
peripheral pool of this metabolite, which is in accordance with our previous result in man and 
with the possibility of 8-OH-EFV to be able to cross the BBB. Other observation was that 
hippocampus is the tissue more susceptible to 8-OH-EFV toxicity (where a decrease in GSSP 
and CysSSP was observed) and this was coincident with a decrease in GSH and an increase of 
GSSP in plasma, suggesting the suitability of plasma thiolomic profile, together with 
8-OH-EFV concentrations in evaluating what happens in brain. New data from our group 
aiming at the translation of this data showed a similar thiolation plasma profile in patients on 
EFV (Correia et al. 2016). Moreover, patients with higher plasmatic GSSP had higher 
8-OH-EFV. This profile was not related to viral load or CD4+ T-cell count of the patients and 
it was independent on viral subtype (subtype B vs non-B). 
 
 
2. What is the added value and the impact of the present work to the field? 
 
Contribution to the knowledge of the mechanisms of EFV neurotoxicity  
We propose that short-term neurotoxic effects would probably be more dependent on EFV 
concentration, while those at long-term will most likely be related to 8-OH-EFV accumulation. 
This issue is pertinent for further evaluation as CNS-adverse reactions occurring in the first 
weeks of treatment (short-term) are normally transient, or if not the patient usually switches to 
other cART options. Thus the long-term effects of EFV exposition in brain are a main concern 
and much more difficult to predict and to manage. This is particularly worrying in children, 
which start EFV at 3 years of age, ideally through their entire life.  
 
Identification of peripheral markers to monitor the risk of long-term mood changes and memory 
impairment and to evaluate strategies for its management 
Our findings suggest for the first time the importance of monitoring 8-OH-EFV, besides EFV, 
to predict and manage EFV-CNS toxicity. Together with evaluation of thiolomic signature as a 
measure of electrophilic stress they can be components of a better index for the risk of long-term 





New input in the interpretation of pharmacogenetic data on CYB2B6 and in the identification 
of new targets for pharmacogenetic studies on EFV neurotoxicity 
These data are also relevant for the interpretation of pharmacogenetic data. Most of 
pharmacogenetic studies are related to CYP2B6 and consider EFV itself as the responsible for 
its toxicity. Consequently, low metabolizers are assumed to be at greater risk for adverse 
reactions. However, it has been not evaluated the correlation between polymorphisms with a 
specific type of adverse reaction, with EFV biotransformation into 8-OH-EFV or with time of 
exposure. Due to this lack of information and considering our results, we suggest that low 
metabolizers are at higher risk of short-term toxicity (due to EFV), while ultra-rapid and 
extensive metabolizers are more prone to long-term toxicity (as mood changes and memory 
impairment). It should be also considered other pharmacogenetic targets as, other CYP 
isoforms, UGTs, the nuclear receptors CAR and PXR, which have been related with EFV PK 
alterations (Swart et al., 2012b) and in glutathione-S-transferase (responsible for catalyze the 
conjugation of electrophiles to GSH for their detoxification), which have been associated with 
increase susceptibility to toxic compounds (Wormhoudt et al., 1999).  
 
Identification of drug interactions and their mechanisms that increase long-term EFV 
neurotoxicity risk 
It is important to consider drug interactions in EFV prescription, since EFV has a narrow 
therapeutic window and HIV-infected patients might develop comorbidities and are often 
polymedicated. Possible targets of drug interactions in the EFV neurotoxicity are the enzymes 
involved in EFV metabolism that contribute to 8-OH-EFV increased concentration, e.g., 
CYP3A4 inhibitors (e.g., ritonavir (Eagling et al., 1997)), CYP2B6 inducers (e.g., rifampicin 
(Faucette et al., 2004)) and UGT2B7 inhibitors (e.g., valproic acid (Trapnell et al., 1998)). It 
should be given attention to the prescription of other inducers of CYP2B6, as the antiepileptic 
drugs phenytoin and carbamazepine, which are inducers of CYP2B6 (Faucette et al., 2004) and 
deplete GSH (Raya et al., 1995). Depletion of GSH is involved in toxicity 
outcomes/susceptibility to toxicity and is present in the plasma, PBMCs and brain lysates of 
HIV-infected patients (de Quay et al., 1992; Saing et al., 2016). For these reasons, attention 
should be also given to drugs and pathologic conditions with associated reduction of GSH 
content. One particular case on drug interactions with EFV is rifampicin, used for tuberculosis. 
Rifampicin is a potent inducer of CYP3A4 and a moderate of CYP2B6 (U. S. Food and Drug 
Administration, 2016), which might lead to sub-therapeutic EFV concentrations, particularly 
in patients with bodyweight above 50 kg (Lopez-Cortes et al., 2002). In 2012, FDA 
recommended the increase of EFV dose from 600 to 800 mg/daily when co-administrated with 
rifampicin (AIDSinfo, 2012). However, several studies do not support this recommendation 
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due to the inter-variability of EFV concentrations (Manosuthi et al., 2006) and genetic factors 
(Manosuthi et al., 2014). Nevertheless, the effect of this co-administration in 8-OH-EFV 
concentrations was not assessed yet.  
 
Contribute to the evaluation of drug bioactivation risk and justify the unquestionable need of 
animal studies in neurotoxicity assessments 
The treatment conditions used in Wistar rat represent a suitable model for the assessment of 
EFV PK/neurotoxicity relationships and to ascertain the mechanisms underlying it. Therefore, 
we believe that this model will permit to get further insights into the molecular mechanism of 
EFV-induced neurotoxicity, and explore not only more possible targets but also uncover drug 
metabolism/bioactivation in brain. Also, we consider that the evaluation in different 
compartments is of unquestionable importance to understand the likelihood of a drug to be 
toxic. Our findings in prefrontal cortex and hippocampus highlight the importance of not study 
the complete brain, since as we and others (Miksys et al., 2000) have observed that Cyp2b has 
tissue- and cell-specificities. Hence, it is important to not assume that the regulation of CYPs 
is the same in all compartments. The same rational must be applied for tissue capability to 
bioactivate 8-OH-EFV and tissue response to electrophilic stress. 
 
The use of an animal model was unavoidable for our research approach, mainly since our study 
involved long-term drug exposure, liver-blood-brain tissues analysis and importantly its 
relation to behavior evaluation. Therefore, the use of in vitro alternatives were not found to be 
suitable.  Importantly, during the entire project the 3Rs policy (replacement, reduction and 
refinement) was always followed. The number of animals used was kept to the minimum and, 
whenever possible, the same tissue was used for more than one assay. Also, NIH Principles of 
Laboratory Animal Care (NIH Publication 85-23, revised 1985), the European guidelines for 
the protection of animals used for scientific purposes (European Union Directive 2010/63/EU) 
and the Portuguese Law nº 113/2013 concerning ethical use of animals were followed. 
 
If translated into clinical practice, the evidence herein provided could be helpful on the 
interpretation and clinical understanding of pharmacogenomics and TDM data in both 
short- and long-term EFV neurotoxicity, as well as on the identification of patients prone to 
toxicity. Moreover, it highlights the awareness of not only of drug-drug interactions with 
chronically used enzyme inducers that cross BBB, but also of drugs that are extensively 






 3. Which were the limitations of the present work? 
 
We are conscious about some limitations of our clinical study. Our sample size should ideally 
be larger; however, in order to avoid bias in our results, we have implemented restricted 
inclusion and exclusion criteria, which decreased significantly our study population. Another 
limitation was the low number for women in our cohort, which did not allow us to evaluate 
sex-differences in the toxicity markers herein explored, despite the reported sex-differences in 
EFV PK (Burger et al., 2006). Additionally, our CNS adverse effects were based on 
self-reported complaints made by the patients. Ideally, these adverse effects would be assessed 
by validated cognitive tests and interviews. 
 
Moreover, we have not quantified 8-OH-EFV-sulfate that was recently identified by Aouri and 
co-authors (2016) as a new phase II metabolite. This metabolite occurs approximately 10 times 
lower than the glucuronide conjugate (Aouri et al., 2016). With this knowledge, not only 
8-OH-EFV-Glc but also 8-OH-EFV-sulfate should have been considered. Currently, it is 
unknown if 8-OH-EFV-Glc and 8-OH-EFV-sulfate pass through BBB. Usually, phase II 
metabolites are unable to cross this barrier; however, there are reported exceptions (D. Wu et 
al., 1997). Particularly in the case of 8-OH-EFV, both phase II metabolites were found in the 
CSF (Aouri et al., 2016) and considering that phase II enzymes content in brain is low (Ouzzine 
et al., 2014), it is possible to postulate that BBB is permeable to EFV phase II metabolites.     
  
In animals, it was only possible to quantify 8-OH-EFV when glucuronidase enzyme was use, 
thus the quantification reflects both the sum of non-conjugated and 8-OH-EFV-Glc fractions. 
Again, 8-OH-EFV-sulfate was not measured despite its identification in rat urine (Mutlib et al., 
1999).  As the rat metabolism is more rapid than man, makes it difficult to quantify the free 
metabolite with the use of HPLC methodology. The identification of the phase II metabolite, 
8-OH-EFV-sulfate in man has implications for the use of EFV as a probe to phenotype the 
CYP2B6 activity. Thus, in the future, sulfatase hydrolysis has also to be performed. Also, other 
limitation arising from the factors mentioned above was the lack of 8-OH-EFV quantification 
in tissues, especially in CNS compartments.  
 
Furthermore, it was not possible to evaluate the formation of covalent adducts between 
8-OH-EFV-derived reactive metabolites and proteins. Despite the oxidative bioactivation 
pathway was demonstrated in vitro (Harjivan et al., 2014; Wanke et al., 2012), to attest the role 
of 8-OH-EFV bioactivation in the onset of EFV-induced neurotoxic events, the identification 
of these protein adducts should have been performed in vivo. Nonetheless, the identification of 
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drug-protein adducts in vivo constitutes still a great analytical challenge, due to the low 
concentration of adducted protein when compared with the concentration of non-modified 
protein. In fact, despite the huge developments in terms of bottom-up mass spectrometry-based 
proteomics approaches towards the identification of covalent drug-protein adducts, this still 
constitutes a time-consuming task. Considerable work is needed, not only for the optimization 
of protein isolation and digestion steps, but also for the optimization of chromatographic and 
mass spectrometry methodologies for the separation and identification of adducted peptide and 
for the subsequent data analysis step. For these reasons, it was not possible to achieve this goal 
within the time-period of this thesis. 
 
Finally, we have not considered the effects of the other drugs of cART regimen, which are not 
exempt of toxicity and of changing EFV PK (Carr and Cooper, 2000).  Moreover, our animal 
model does not explore the contribution of HIV-infection and its associated 
immunosuppression, residual inflammation and viremia to neurotoxicity. Nowadays, it is 
possible to develop humanized mouse models with HIV (Denton and García, 2011). These 
models are generated by transplanting human cells or tissues into genetically modified 
immunodeficient mice. These animals are then susceptible to infection through the natural 
routes by which humans are. With these models, it would be possible to study cART toxicity 
outcomes in parallel with the effects of HIV-infection. Regarding CNS status, this is of 
particular importance, since HIV also generates neurocognitive disorders (Letendre, 2011).  
This association has also been linked to a higher oxidative stress status.  
 
 
4. What is still unknown and should be addressed? 
  
Despite the significant progress in recent years, there are still large gaps in the current 
knowledge of the effects of drug biotransformation in adverse neurological events. Further 
studies must be conducted to elucidate the importance of 8-OH-EFV concentrations towards 
personalized and safer prescription of EFV. We believe that it is necessary to define an 
8-OH-EFV concentration threshold above which the risk of toxicity increases, similar to what 
exists for EFV (> 4 mg/L). Pharmacogenetic results with short- and long-term toxicity appear 
to be of interest too.   
 
The hypothesis of adducts formation in brain, particularly between bioactivated 8-OH-EFV and 
synaptic proteins in these times of exposure to the drug should also be addressed. Another 




not, would it be useful to perform structural modifications of EFV molecule in order to avoid 
8-OH-EFV formation? The proximity of the OH group at position 8 to the nitrogen group in 
the benzoxazine structure appears to be critical for the generation of neurotoxic metabolites. 
This is demonstrated by the fact that 7-OH-EFV, which possesses a OH group at the carbon-7 
position, is not neurotoxic. Consequently, is it possible to hypothesize that the substitution of 
the carbon at position 8 (e.g. with a fluorine), avoiding EFV hydroxylation at this position, 
should produce a compound with decreased neurotoxicity.  
 
Future work should also explore thiolomic profile monitoring to assess the usefulness of 
intervention strategies against electrophilic stress prior to or early after the onset of clinical 
symptoms upon EFV exposure. For example, it will be interesting to evaluate the contribution 
of polymorphisms in GSH-related genes or thiolation profiles, not only for the evaluation EFV 
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Informação ao participante voluntário no estudo intitulado Deteção 
de Efavirenz e de adutos de proteínas em indivíduos infetados pelo VIH 
 
É	seguido	nesta	consulta	por	estar	infetado	VIH	e	está	no	momento	a	ser	




Numa	 tentativa	 de	 podermos	 identificar	 possíveis	 efeitos	 adversos	 não	
esperados	dos	medicamentos,	agradecemos	a	sua	colaboração	na	colheita	de	uma	
amostra	 do	 seu	 sangue	 para	 realização	 de	 testes	 laboratoriais	 específicos	 que	
detetem	eventuais	toxicidades.	Esta	amostra	de	sangue	será	colhida	em	consulta	
e	serão	apenas	colhidos	3	ml	de	sangue.	A	sua	participação	será	voluntária,	não	
sendo	 paga	 qualquer	 quantia	 pela	 sua	 contribuição	 no	 estudo.	 O	 seu	 médico	
assistente	 também	 não	 receberá	 nenhuma	 remuneração	 pela	 realização	 deste	
estudo.	 Os	 dados	 relativos	 à	 sua	 colheita	 estarão	 protegidos	 pela	 lei	 da	
confidencialidade	e	proteção	de	dados.		
O	presente	estudo	não	 trará	qualquer	benefício	direto	para	 si	ou	para	a	
evolução	 da	 sua	 infeção.	 Com	 este	 estudo	 pretendemos	 saber	 mais	 sobre	 os	
medicamentos	que	utiliza	e	com	os	dados	colhidos	esperamos	chegar	a	conclusões	
que	no	futuro	possam	contribuir	para	o	melhor	conhecimento	dos	medicamentos	






























Patient data notebook 
 
































Data	de	nascimento |DD|MM|AA|  





Consumo	de	álcool																		N	¨					S	¨          
	
Uso	de	drogas	injectáveis     N		¨    S ¨                                                                 Fumador(a)	 N		¨    Y ¨   
 
Reacções	adversas																	N		¨     S	¨   
 
Patologias	associadas												N		¨          HCV	¨											HBV		¨											Diabetes	¨										Outra	¨		
	
Infecções	oportunistas			       N		¨          Tuberculose	 ¨           Outra	¨	                                                                                              	
                                                            
 




|___|___| |___|___| |___|___| 
|___|___| |___|___| |___|___| 
|___|___| |___|___| |___|___| 
















































|___|___| |___|___| |___|___| |___|___|___|___|	 |___|	
NOME	DO	FÁRMACO	
|___|___| |___|___| |___|___| |___|___|___|___|	 |___|	
NOME	DO	FÁRMACO	
|___|___| |___|___| |___|___| |___|___|___|___|	 |___|	
NOME	DO	FÁRMACO	
|___|___| |___|___| |___|___| |___|___|___|___|	 |___|	
NOME	DO	FÁRMACO	
|___|___| |___|___| |___|___| |___|___|___|___|	 |___|	
Outros	fármacos	Não	c						Sim	c	(incluir	todos	os	que	tomou	no	último	mês)     
 (incluir	fitoterápicos,	medicamentos	de	venda	livre,	etc.) 	
NOME	DO	FÁRMACO	
|___|___| |___|___| |___|___| |___|___|___|___|	 |___|	
NOME	DO	FÁRMACO	
|___|___| |___|___| |___|___| |___|___|___|___|	 |___|	
NOME	DO	FÁRMACO	
|___|___| |___|___| |___|___| |___|___|___|___|	 |___|	
NOME	DO	FÁRMACO	








¨ cel/mm3	 ¨ ________	 |DD|MM|AA| 
Subpopulações	de	CD8	 |___|___|___|___|___|___| ¨ cel/mm3 ¨ ________	 |DD|MM|AA|	
Carga	viral	  
|___|___|___|___|___|___| ¨ cópias/mL	 ¨ ________ |DD|MM|AA| 
Hemoglobina		
|___|___|___|___|___|___| ¨ g/dL	 ¨ ________ |DD|MM|AA| 
Plaquetas	
|___|___|___|___|___|___| 
¨ cel/mm3 ¨ ________ |DD|MM|AA| 
Leucócitos		
|___|___|___|___|___|___| 
¨ g/L	 ¨ ________ |DD|MM|AA| 
Neutrófilos	
|___|___|___|___|___|___| ¨ cel/mm
3	 ¨ ________ |DD|MM|AA| 
Linfócitos		
|___|___|___|___|___|___| ¨ cel/mm
3	 ¨ ________ |DD|MM|AA| 
Monócitos		
|___|___|___|___|___|___| ¨ cel/mm
3 ¨ ________ |DD|MM|AA| 
Tempo	de	protrombina	(INR)		



















|___|___|___|___|___|___| ¨ mg/dL	 ¨ ________ |DD|MM|AA| 
Glicémia	
|___|___|___|___|___|___| ¨ mg/dL	 ¨ ________ |DD|MM|AA| 
Creatinina	
|___|___|___|___|___|___| 
¨ mg/dL ¨ ________ |DD|MM|AA| 
Ureia	
|___|___|___|___|___|___| ¨ mg/dL	 ¨ ________ |DD|MM|AA| 
Albumina	
|___|___|___|___|___|___| ¨ g/L	 ¨ ________ |DD|MM|AA| 
AST	
|___|___|___|___|___|___| ¨ U/L	 ¨ ________ |DD|MM|AA| 
ALT	
|___|___|___|___|___|___| ¨ U/L	 ¨ ________ |DD|MM|AA| 
g-GT	
|___|___|___|___|___|___| ¨ U/L ¨ ________ |DD|MM|AA| 
Fosfatase	alcalina	 |___|___|___|___|___|___| ¨ U/L	 ¨ ________ |DD|MM|AA| 
LDH	 |___|___|___|___|___|___|	 ¨ U/L ¨ ________ |DD|MM|AA| 
Bilirrubina	total	 |___|___|___|___|___|___|	 ¨ mg/dL ¨ ________ |DD|MM|AA| 
Bilirrubina	directa	 |___|___|___|___|___|___| ¨ mg/dL	 ¨ ________ |DD|MM|AA| 
PCR	 |___|___|___|___|___|___|	 ¨ mg/dL ¨ ________ |DD|MM|AA| 
Ácido	hialurónico	 |___|___|___|___|___|___|	 ¨ mg/dL ¨ ________ |DD|MM|AA| 
Haptoglobina		
|___|___|___|___|___|___| ¨ µg/dL ¨ ________ |DD|MM|AA| 
Alfa2-macroglobulina	
|___|___|___|___|___|___| ¨ g/dL ¨ ________ |DD|MM|AA| 
Apolipoproteina	A1	
|___|___|___|___|___|___| ¨ mg/dL ¨ ________ |DD|MM|AA| 
Colesterol	total		
|___|___|___|___|___|___| ¨ mg/dL ¨ ________ |DD|MM|AA| 
LDL	–	col	
|___|___|___|___|___|___| ¨ mg/dL ¨ ________ |DD|MM|AA| 
HDL	-	col	
|___|___|___|___|___|___| ¨ mg/dL ¨ ________ |DD|MM|AA| 
Triglicéridos	
|___|___|___|___|___|___| ¨ mg/dL	 ¨ ________ |DD|MM|AA| 
Transferrina	
|___|___|___|___|___|___| ¨ g/L ¨ ________ |DD|MM|AA| 
Ferro	
|___|___|___|___|___|___| ¨ μg/dL ¨ ________ |DD|MM|AA| 
Sódio	
|___|___|___|___|___|___| ¨ mmol/L ¨ ________ |DD|MM|AA| 
Potássio	
|___|___|___|___|___|___| ¨ mmol/L ¨ ________ |DD|MM|AA| 
MPKA	
|___|___|___|___|___|___| ¨  ¨ ________ |DD|MM|AA| 
CPK	

































Responsável pela recolha de dados _________________________________________________________________________________ 
 
	
	
